



**Proven Ability In Life Sciences**

**SEQUENT SCIENTIFIC LIMITED**

**CIN: L99999TS1985PLC196357**

**Registered Office:** 3<sup>rd</sup> Floor, Srivallis Corporate, Plot No.  
290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,  
Hyderabad, Shaikpet, Telangana, India, 500033 **Tel No:** +91 22  
4111 4777 | **Email:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)  
**Website:** [www.sequent.in](http://www.sequent.in)

**NOTICE CONVENING MEETING OF EQUITY SHAREHOLDERS OF  
SEQUENT SCIENTIFIC LIMITED PURSUANT TO ORDER DATED JULY 23,  
2025 OF THE HON'BLE NATIONAL COMPANY LAW TRIBUNAL,  
HYDERABAD BENCH - II**

<b>MEETING</b>	
<b>Day and Date</b>	<b>Saturday, August 30, 2025</b>
<b>Time</b>	<b>10:00 a.m. (IST)</b>
<b>Mode of Meeting</b>	As per the directions of the <b>Hon'ble National Company Law Tribunal, Hyderabad Bench - II</b> , the meeting shall be conducted through video conferencing ("VC")/Other Audio-Visual Means ("OAVM")
<b>Cut-off date for e-voting</b>	<b>August 22, 2025</b>
<b>Remote e-voting start date and time</b>	<b>August 26, 2025 at 9:00 a.m. (IST)</b>
<b>Remote e-voting end date and time</b>	<b>August 29, 2025 at 5:00 p.m. (IST)</b>

**FORM NO. CAA-2**

*[Pursuant to Section 230(3) of the Companies Act, 2013 and Rules 6 and 7 of Companies (Compromises, Arrangements and Amalgamation) Rules, 2016]*

**BEFORE THE HON'BLE NATIONAL COMPANY LAW TRIBUNAL,**

**HYDERABAD BENCH - II**

**COMPANY APPLICATION (CAA) NO. 30/230/HDB/2025**

**IN THE MATTER OF SECTIONS 230 TO 232**

**AND OTHER APPLICABLE PROVISIONS**

**OF THE COMPANIES ACT, 2013**

**AND**

**IN THE MATTER OF COMPOSITE SCHEME OF AMALGAMATION**

**AMONGST**

**SEQUENT SCIENTIFIC LIMITED**

**(APPLICANT COMPANY 1/AMALGAMATED COMPANY)**

**AND**

**SYMED LABS LIMITED**

**(APPLICANT COMPANY 2/TRANSFEROR COMPANY 1)**

**AND**

**VANDANA LIFE SCIENCES PRIVATE LIMITED**

**(APPLICANT COMPANY 3/TRANSFEROR COMPANY 2)**

**AND**

**APPCURE LABS PRIVATE LIMITED**

**(APPLICANT COMPANY 4/TRANSFEROR COMPANY 3)**

**AND**

**VINDHYA PHARMA (INDIA) PRIVATE LIMITED**

**(APPLICANT COMPANY 5/TRANSFEROR COMPANY 4)**

**AND**

**S.V. LABS PRIVATE LIMITED**

**(APPLICANT COMPANY 6/TRANSFEROR COMPANY 5)**

**AND**

**VINDHYA ORGANICS PRIVATE LIMITED**

**(APPLICANT COMPANY 7/TRANSFEROR COMPANY 6)**

**AND**  
**VIYASH LIFE SCIENCES PRIVATE LIMITED**  
**(APPLICANT COMPANY 8/TRANSFEREE COMPANY 1/AMALGAMATING**  
**COMPANY 1)**

**AND**  
**GENINN LIFE SCIENCES PRIVATE LIMITED**  
**(APPLICANT COMPANY 9/TRANSFEREE COMPANY 2/TRANSFEROR**  
**COMPANY 7)**

**AND**  
**SEQUENT RESEARCH LIMITED**  
**(APPLICANT COMPANY 10/AMALGAMATING COMPANY 2)**

**AND**  
**AND THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS**

**SEQUENT SCIENTIFIC LIMITED**

(CIN: L99999TS1985PLC196357)

A Company registered under Companies Act of 1956

Having its registered office at 3rd Floor, Srivallis Corporate,

Plot No. 290, SYN 33 34 PTO 39, Guttala Begumpet,

Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033.

**Represented by Mr. Rajaram Narayanan, Authorised Signatory**

**... Applicant Company 1/Amalgamated Company**

**SYMED LABS LIMITED**

(CIN: U24231TG1998PLC029961)

A Company registered under the Companies Act of 1956

Having its registered office at Plot No. 290, Srivallis Corporate,

Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana 500081.

**Represented by Ms. Janaki Aasani, Authorised Signatory**

**... Applicant Company 2/Transferor Company 1**

**VANDANA LIFE SCIENCES PRIVATE LIMITED**

(CIN: U24239TG2002PTC040132)

A Company registered under Companies Act of 1956

Having its registered office at Plot No. 290, Srivallis Corporate,

Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana 500081.

**Represented by Mr. Janaki Aasani, Authorised Signatory**

**... Applicant Company 3/Transferor Company 3**

**APPCURE LABS PRIVATE LIMITED**

(CIN: U24232TG2012PTC084625)

A Company registered under Companies Act of 1956.

Having its registered office at 89/A, Sy. 311/5 Phase – 1, Medchal,

Malkajgiri, IDA Jeedimetla, Hyderabad, Telangana, 500055.

**Represented by Mr. Ramakant Singani, Authorised Signatory**

**... Applicant Company 4/Transferor Company 4**

**VINDHYA PHARMA (INDIA) PRIVATE LIMITED**

(CIN: U24296TG2006PTC050700)

A Company registered under Companies Act of 1956

Having its registered office at Plot No. 290, Srivalli's Corporate,

Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana 500081.

**Represented by Mr. Ramakant Singani, Authorised Signatory**

**... Applicant Company 5/Transferor Company 4**

**S.V. LABS PRIVATE LIMITED**

(CIN: U24239TG2003PTC041662)

A Company registered under Companies Act of 1956

Having its registered office at Plot No. 290, Srivalli's Corporate, Road No. 6,

Kakatiya Hills, Madhapur, Hyderabad, Telangana 500081.

**Represented by Mr. Janaki Aasani, Authorised Signatory**

**... Applicant Company 6/Transferor Company 5**

**VINDHYA ORGANICS PRIVATE LIMITED**

(CIN: U24110TG1988PTC008252)

A Company registered under Companies Act of 1956

Having its registered office at Plot No. 3, 4 & 5,

Anrich Industrial Estate, Bollaram, Telangana 502325.

**Represented by Mr. Janaki Aasani, Authorised Signatory**

**... Applicant Company 7/Transferor Company 6**

**VIYASH LIFE SCIENCES PRIVATE LIMITED**

(CIN: U24239TG2019PTC130774)

A Company registered under Companies Act of 2013

Having its registered office at Plot No. 290, Srivalli's Corporate, Road No. 6,

Kakatiya Hills, Madhapur, Hyderabad, Telangana 500081.

**Represented by Mr. Ramakant Singani, Authorised Signatory**

**... Applicant Company 8/Transferor Company 6**

**GENINN LIFE SCIENCES PRIVATE LIMITED**

(CIN: U24299TG2019PTC136520)

A Company registered under Companies Act of 2013

Having its registered office at Plot No. 3,4 & 5, Anrich Industrial  
Estate Bollaram, Medak, Hyderabad, Telangana, 502325.

**Represented by Mr. Ramakant Singani, Authorised Signatory**

**... Applicant Company 9/Transferee Company 2/Transferor Company 7**

**SEQUENT RESEARCH LIMITED**

(CIN: U24232TL2007PLC042483)

A Company registered under Companies Act of 2013

Having its registered office at 3rd Floor, Srivallis Corporate,

Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet,

Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033.

**Represented by Mr. Rajaram Narayanan, Authorised Signatory**

**... Applicant Company 10/Amalgamating Company 2**

***(Together called as “Applicant Companies”)***

*Further, Transferor Company 1, Transferor Company 2, Transferor Company 3, Transferor Company 4, Transferor Company 5, together called as “**Transferor Companies**”; Amalgamating Company 1 and Amalgamating Company 2 together called as “**Amalgamating Companies**”.*

---

**NOTICE CONVENING MEETING OF EQUITY SHAREHOLDERS OF  
SEQUENT SCIENTIFIC LIMITED**

**To,**

**All the Equity Shareholders of Sequent Scientific Limited**

1. **NOTICE** is hereby given that, by the Order dated 23/07/2025 passed by the Hon’ble National Company Law Tribunal, Hyderabad Bench - II (“Hon’ble **Tribunal**”) in the abovementioned Application in relation to the Composite Scheme, directed to conduct meeting of the Equity Shareholders of Sequent Scientific to be held on **Saturday, August 30, 2025 at 10:00 a.m. (IST)** for the purpose of considering and approving, the

proposed Composite Scheme of Amalgamation amongst Sequent Scientific Limited (“**Company**” or “**Applicant Company 1**” or “**Amalgamated Company**”), Symed Labs Limited (“**Applicant Company 2**” or “**Transferor Company 1**”), Vandana Life Sciences Private Limited (“**Applicant Company 3**” or “**Transferor Company 2**”), Appcure Labs Private Limited (“**Applicant Company 4**” or “**Transferor Company 3**”), Vindhya Pharma (India) Private Limited (“**Applicant Company 5**” or “**Transferor Company 4**”), S.V. Labs Private Limited (“**Applicant Company 6**” or “**Transferor Company 5**”), Vindhya Organics Private Limited (“**Applicant Company 7**” or “**Transferor Company 6**”), Viyash Life Sciences Private Limited (“**Applicant Company 8**” or “**Transferee Company 1**” or “**Amalgamating Company 1**”), Geninn Life Sciences Private Limited (“**Applicant Company 9**” or “**Transferee Company 2**” or “**Transferor Company 7**”), Sequent Research Limited (“**Applicant Company 10**” or “**Amalgamating Company 2**”) and their respective shareholders and creditors (“**Composite Scheme**”) (“**Meeting**”). The Applicant Company 1, Applicant Company 2, Applicant Company 3, Applicant Company 4, Applicant Company 5, Applicant Company 6, Applicant Company 7, Applicant Company 8, Applicant Company 9, Applicant Company 10 are hereinafter collectively referred to as the “**Applicant Companies**”. The brief proposed Composite Scheme finds a mention at Para Number 4 of this Notice.

2. **The shareholding pattern of Promoter/Promoter Group and Public Shareholders of the Amalgamated Company before and after implementation of Scheme is depicted as under:**

**As advised by BSE and NSE in their respective observation letters dated 26<sup>th</sup> May 2025, the shareholding pattern of Promoter/Promoter Group and Public Shareholders before and after implementation of Composite Scheme is set**

out below along with a brief description of the impact of the change in shareholding of the Amalgamated Company:

<b>Category</b>	<b>Pre-Scheme Shareholding (%)</b>	<b>Post-Scheme Shareholding (%)</b>	<b>Change (%)</b>
<b>Promoter/Promoter Group</b>	<b>52.78</b>	<b>62.44</b>	<b>9.66</b>
<b>Public Shareholders</b>	<b>47.05</b>	<b>37.46</b>	<b>(9.59)</b>
<b>Non Promoter/ Non Public</b>	<b>0.17</b>	<b>0.10</b>	<b>(0.07)</b>

The shareholders may note that implementation of scheme shall result in increase in the shareholding of Promoter/Promoter Group from 52.78% to 62.44%. Shareholders may also note that approval of the shareholders to scheme of merger would also result in them agreeing to increase in shareholding of promoters on implementation of the scheme. Therefore, investors should read all the scheme related documents before exercising their voting rights.

Pursuant to effectiveness of the Composite Scheme, as consideration for the amalgamation, the Amalgamated Company will issue equity shares to the eligible shareholders of the Transferee Company 1, as per the share exchange ratio determined under the Valuation Report.

There will be no impact on the rights of public shareholders of the Amalgamated Company, as a result of the merger, and the parties have followed due process, and obtained all necessary approvals, made applicable



**disclosures as per the provisions of the Act, the SEBI Listing Regulations, relevant rules, regulations, circulars, etc. notified thereunder, and orders of regulatory authorities, including the SEBI, BSE, NSE, and the Competition Commission of India, as applicable.**

3. In pursuance of the aforesaid Order and as directed therein further notice is hereby given that a meeting of the Equity Shareholders of the Sequent Scientific Limited will be held through video conferencing (“VC”) /Other Audio Visual Means (“OAVM”) on **Saturday, August 30, 2025 at 10.00 a.m. (IST)** at which time the Equity Shareholders of the Sequent Scientific Limited are requested to attend the same.
4. In compliance with the applicable provisions of the Companies Act, 2013 (“Act”) and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”) to consider, and if thought fit, to pass, the following resolution for approval of the Composite Scheme of Arrangement is proposed for consideration and approval by the shareholders of the Company, by the requisite majority as prescribed under Section 230(6) of the Companies Act, 2013 and subject to the condition that the number of votes cast by the public shareholders in favour of the resolution shall be more than the number of votes cast against it, in accordance with the requirements of the SEBI Master Circular:

***“RESOLVED THAT in accordance with the provisions of Sections 230 to 232 read with other applicable provisions of the Companies Act, 2013 (including any statutory modification(s) or re-enactment thereof, for the time being in force), the rules including the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, circulars and notifications made thereunder and the Securities and Exchange Board of India (“SEBI”) (Listing Obligations and***

*Disclosure Requirements) Regulations, 2015 (as amended from time to time), read with the Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated 20<sup>th</sup> June, 2023 issued by the SEBI and other circulars/guidelines issued by SEBI as may be applicable to the Composite Scheme of amalgamation from time to time, the observation letters dated 26<sup>th</sup> May 2025 issued by BSE Limited and National Stock Exchange of India Limited respectively and other relevant provisions of the Income-tax Act, 1961 and rules made thereunder and all other provisions of the applicable laws, or any amendments thereto or modifications thereof, the Memorandum and Articles of Association of the Company, and subject to the approval of the Hon'ble National Company Law Tribunal, Hyderabad bench ("NCLT") and such other approvals as may be necessary or as may be directed by the Hon'ble NCLT or by any regulatory authorities, while granting such approvals, permissions and sanctions, which may be agreed to by the Board of Directors of the Company (hereinafter referred to as the "**Board**"), which term shall be deemed to mean and include one or more Committee(s) constituted/to be constituted by the Board or any person(s) which the Board may nominate to exercise its powers including the powers conferred by this resolution), the Composite Scheme of amalgamation amongst Sequent Scientific Limited (Amalgamated Company) and Symed Labs Limited (Transferor Company 1), Vandana Life Sciences Private Limited (Transferor Company 2), Appcure Labs Private Limited (Transferor Company 3), Vindhya Pharma (India) Private Limited (Transferor Company 4), S.V. Labs Private Limited (Transferor Company 5), Vindhya Organics Private Limited (Transferor Company 6), Viyash Life Sciences Private Limited (Transferee Company 1/Amalgamating Company 1), Geninn*

*Life Sciences Private Limited (Transferee Company 2/Transferor Company 7), Sequent Research Limited (Amalgamating Company 2) and their respective Shareholders and Creditors (“Composite Scheme”) be and is hereby approved.”*

*“RESOLVED FURTHER THAT for the purpose of giving effect to this resolution and for removal of any difficulties or doubts, the Board, be and is hereby authorized to do all such acts, deeds, matters and things, as it may, in its absolute discretion, deem desirable, necessary, expedient, usual or proper, and to settle any questions or difficulties or doubts that may arise, including passing of such accounting entries and /or making such adjustments in the books of accounts, transfer/vesting of such assets and liabilities as considered necessary to give effect to the above resolution, settling of any questions or difficulties arising under the Composite Scheme or in regard to and of the meaning or interpretation of the Composite Scheme or implementation thereof or in any matter whatsoever connected therewith, or to review the position relating to the satisfaction of various conditions of the Composite Scheme and if necessary, to waive any of those, and to make modifications, amendments, revisions, edits and all other actions as may be required to finalise the Composite Scheme and do all acts, deeds and things as may be necessary, desirable or expedient for carrying the Composite Scheme into effect or to carry out such modifications/directions as may be required and/or imposed and/or permitted by the NCLT while sanctioning the Composite Scheme, or by any regulatory authorities, to do and perform and to authorize the performance of all such acts and deeds which are necessary or advisable for the implementation of the Composite Scheme and upon*

*the sanction of the Composite Scheme by, amongst others, the NCLT, SEBI and/or any other regulatory/government authorities, to implement and to make the Composite Scheme effective, without the Board being required to seek any further consent/approval of the shareholders, and/or to approve withdrawal (and where applicable, re-filing) of the Composite Scheme at any stage for any reason including in case any changes and/or modifications are suggested/required to be made in the Composite Scheme or any condition suggested, required or imposed, whether by any shareholder and/or creditor of the Company, the SEBI, the NCLT, and/or any other authority, are in its view not acceptable to the Company, and/or if the Composite Scheme cannot be implemented otherwise, and to do all such acts, deeds and things as it may deem necessary and desirable in connection therewith and incidental thereto, to approve and authorize execution of any agreements, deeds, documents, declarations, affidavits, writings, etc. (including any alterations or modifications in the documents executed or to be executed), whether or not under the Common Seal of the Company, as may be required from time to time in connection with the Composite Scheme.”*


**“TAKE FURTHER NOTICE** that the equity shareholders shall have the facility and option of voting on the resolution for approval of the Composite Scheme either by casting their votes: (a) through electronic voting system available at the Meeting to be held through VC/OAVM (**“e-voting at the Meeting”**); or (b) by remote electronic voting (**“remote e-voting”**) during the period as stated below:

<b><i>Remote e-Voting Period</i></b>	
<b><i>Commencement of remote e-voting</i></b>	<b><i>Tuesday, August 26, 2025 at 9:00 a.m. (IST)</i></b>
<b><i>Conclusion of remote e-voting</i></b>	<b><i>Friday, August 29, 2025 at 5:00 p.m. (IST)</i></b>

*A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e., Friday, August 22, 2025 (“Cut-Off Date”) only shall be entitled to exercise his/her/its voting rights on the resolution proposed in the Notice and attend the Meeting. A person who is not an equity shareholder as on the Cut-Off Date, should treat this Notice for information purpose only.”*

5. The explanatory statement under Sections 230 and 232 read with Section 102, other applicable provisions of the Act and Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 (“CAA Rules”) along with all annexures to such statement, including a copy of the Composite Scheme are annexed hereto and can be obtained free of charge at the registered office of the Sequent Scientific Limited expect for those Equity Shareholders whose email ID is not available for whom weblink provided below. A copy of this Notice, a copy of the Tribunal Order and the accompanying documents are also placed on the:

- (i) website of the Company and can be accessed at <https://sequent.in/wp-content/uploads/2025/07/NCLT-Notice-of-Equity-shareholders-.pdf> or;

by scanning the QR code	
-------------------------	---

- (ii) website of National Securities Depository Limited (“NSDL”), being the agency appointed by the Company to provide the e-voting and other facilities for convening of the Meeting at <https://www.evoting.nsdl.com/>
  - (iii) website of the Stock Exchanges i.e., BSE viz. <https://www.bseindia.com/> and NSE viz. <https://www.nseindia.com/>.
6. The Hon’ble NCLT has appointed Mr. Manav Gecil Thomas, Advocate, as the Chairperson and Mr. Venka Reddy Bathina, Practicing Company Secretary, as the Scrutinizer of the said Meeting.
  7. The Scrutinizer shall, after the conclusion of the Meeting, submit a consolidated Scrutinizer’s report of the total votes cast in favor and against the resolution and invalid votes, if any and submit the same to the Chairperson of the Meeting or a person authorized by Chairperson in writing who shall countersign the same.
  8. The voting results shall be declared by the Chairperson of the Meeting within 2 (two) working days from the conclusion of the Meeting and the same shall be displayed on the notice board of the Company at its registered office and posted on the website of the Company at <https://sequent.in/> and NSDL at <https://www.evoting.nsdl.com/>. The results shall also be forwarded to BSE and the NSE where the Company’s shares are listed.
  9. The resolution for approval of the Composite Scheme shall, if passed by a majority in number representing three-fourths in value of the Shareholders of the Company casting their

votes, as aforesaid, pursuant to Section 230(6) of the Act, shall be deemed to have been duly passed on the date of the Meeting i.e., Saturday, August 30, 2025. Further, the Composite Scheme shall be acted upon only if the votes cast by the public shareholders in favour of the Composite Scheme are more than the number of votes by the public shareholders against it as per the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated 20<sup>th</sup> June 2023.

10. The Composite Scheme, if approved at the Meeting, will be subject to the subsequent sanction of the Tribunal and such other approvals, permissions and sanctions of regulatory or other authorities, as may be necessary.

**Manav Gecil Thomas**  
**Chairperson of the Meeting**  
**appointed by the Hon'ble Tribunal**

Date: **28<sup>th</sup> July 2025**

Place: **Hyderabad**



## **NOTES FOR THE MEETING**

### **GENERAL INSTRUCTIONS FOR ACCESSING AND PARTICIPATING IN THE MEETING THROUGH VC/OAVM FACILITY AND VOTING THROUGH ELECTRONIC MEANS INCLUDING REMOTE E-VOTING**

1. Pursuant to the Tribunal Order, the Meeting of the equity shareholders of the Company will be held through VC/OAVM to transact the business set out in this Notice. Equity shareholders attending the Meeting through VC/OAVM shall be reckoned for the purpose of quorum. Quorum for the Meeting shall be in terms of Section 103 of the Act. Further, in terms of the Tribunal Order, in the event the aforesaid quorum for the Meeting is not present at the commencement of the Meeting then the Meeting shall be adjourned by 30 minutes and thereafter the equity shareholders present at the Meeting shall be deemed to constitute requisite quorum.
2. Since the Meeting is being held through VC/OAVM, physical attendance of the equity shareholders has been dispensed with. Accordingly, the facility for appointment of proxies by the equity shareholders will not be available for the Meeting. Hence, proxy forms and attendance slips are not annexed to this Notice.
3. The proceedings of this Meeting shall be deemed to have been conducted at the venue being registered office of the Company located at 3<sup>rd</sup> Floor, Srivallis Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India, 500033 which shall be the deemed venue of the Meeting. The route map for the Meeting is not attached as the Meeting is being held through VC/OAVM.
4. Pursuant to provisions of Section 113 of the Act, authorized representatives of institutional/corporate equity shareholders (i.e. other than individuals/Hindu Undivided Family) may be appointed for the purpose of voting through remote e-voting, for participation in the Meeting through VC/OAVM facility and e-voting at the Meeting. Such institutional/corporate shareholders are required to send a signed legible copy of its relevant board or governing body resolution/power of attorney/authority letter, etc., to the Scrutinizer by e-mail (in PDF/JPEG Format) at [bvracs123@gmail.com](mailto:bvracs123@gmail.com) with a copy marked to the Company at [investorrelations@sequent.in](mailto:investorrelations@sequent.in) and NSDL at [evoting@nsdl.com](mailto:evoting@nsdl.com) or in physical mode at the registered office of the Company, at least 48 hours before the Meeting with the subject line “**Sequent Scientific Limited NCLT Convened Meeting**”.
5. The Notice of the Meeting and the accompanying documents mentioned in the Index are being sent only through:
  - a) electronic mode to those equity shareholders whose e-mail addresses are registered/available with the Company/Registrar & Transfer Agent /Depository participant(s) /Depositories; and
  - b) speed post/registered post to those equity shareholders whose e-mail addresses are not available with the Company.



6. The Company has made arrangements with NSDL to provide the facility for voting by the equity shareholders through remote e-voting, for participation in the Meeting through VC/OAVM and e-voting at the Meeting.
7. The Notice, Scheme, statement under Sections 230 and 232 read with other applicable provisions of the Act and Rule 6 of the CAA Rules and all other accompanying documents are enclosed herewith and shall be available for inspection on the Company's website at <https://sequent.in/>.
8. If so desired, equity shareholders may obtain a physical copy of the Notice and the accompanying documents, i.e., Scheme and the statement under Section 230 read with other applicable provisions of the Act and Rule 6 of the CAA Rules, free of charge. A written request in this regard, along with the details of shareholding in the Company may be addressed to the Company Secretary at [investorrelations@sequent.in](mailto:investorrelations@sequent.in).
9. Subject to: (i) the receipt of the requisite majority of votes in favour of the Composite Scheme, that is, a majority in number representing three-fourths in value of the shareholders voting, as required under Sections 230 to 232 of the Companies Act, 2013, and (ii) the votes cast by the public shareholders in favour of the Composite Scheme being more than the votes cast by the public shareholders against it, in accordance with the SEBI Master Circular No. SEBI/ HO/CFD/POD-2/P/CIR/2023/93 dated 20<sup>th</sup> June 2023, the Resolution as set out in the Notice shall be deemed to have been passed on the date of the Meeting (as specified in the Notice), and the votes cast through remote e-voting and e-voting at the Meeting shall be considered for this purpose.
10. In case of joint equity shareholders attending the Meeting, only such joint equity shareholder who is higher in the order of names will be entitled to vote at the Meeting.
11. The voting rights of the equity shareholders shall be in proportion to their shareholding of the paid-up equity share capital of the Company as on cut-off date as mentioned in the Notice.
12. The Notice convening the Meeting will be published through advertisement in "Business Standard" English Newspaper and "Nava Telangana" (Telugu) Vernacular Newspaper respectively.

#### **PROCEDURE FOR JOINING THE MEETING THROUGH VC/OAVM :**

13. The equity shareholders will be provided with a facility to attend the Meeting through VC/OAVM through the NSDL e-Voting system. The equity shareholders may access the same by following the steps mentioned below for **Access to NSDL e-voting system**. The link for VC/OAVM will be available in "**Shareholder/Member/Creditor login**" where the EVEN ("**E-voting Event Number**") of the Company will be displayed. After successful login, the equity shareholders will be able to see the link of "**VC/OAVM**" placed under the tab "**Join Meeting**" against the name of the Company. On clicking this link, the equity shareholders will be able to attend the Meeting. Please note that the equity shareholders who do not have the User ID and Password for e-voting or have forgotten the

User ID /Password may retrieve the same by following the remote e-voting instructions mentioned below to avoid last minute rush.

14. The equity shareholders may join the Meeting through laptops, smartphones and tablets. Further, the equity shareholders will be required to use Internet with a good speed to avoid any disturbance during the Meeting. The equity shareholders will need the latest version of Chrome, Safari, Internet Explorer 11, MS Edge or Firefox. Please note that equity shareholders connecting from smartphones or tablets or through laptops connecting via mobile hotspot may experience audio/video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.
15. The equity shareholders desirous of getting any information about the matter to be considered at the Meeting are requested to write to the Company 7 (Seven) days in advance of the Meeting i.e. by 5.00 p.m. (IST) on Saturday, August 23, 2025, at [investorrelations@sequent.in](mailto:investorrelations@sequent.in) from their registered e-mail address, mentioning their name, DP ID and Client ID /folio number and mobile number.
16. The equity shareholders who would like to express their views/ask questions as a speaker at the Meeting are requested to pre-register themselves by sending a request from their registered e-mail address mentioning their names, DP ID and Client ID /folio number and mobile number at [investorrelations@sequent.in](mailto:investorrelations@sequent.in), 7 (**Seven**) days in advance of the Meeting i.e. by 5.00 p.m. (IST) on Saturday, August 23, 2025. Only those equity shareholders who have pre-registered themselves as a speaker will be allowed to express their views/ask questions during the Meeting. The Company reserves the right to restrict the number of speakers depending on the availability of time for the Meeting.
17. The equity shareholders can join the Meeting in the VC/OAVM mode **30 (Thirty)** minutes before the scheduled start time of the Meeting and will remain open throughout the Meeting by following the procedure mentioned in the Notice of Meeting.
18. Participants who need technical assistance before or during the Meeting to access and participate in the Meeting may contact NSDL on 022-48867000 or contact **Ms. Pallavi Mhatre, Senior Manager, NSDL at [evoting@nsdl.com](mailto:evoting@nsdl.com)**.

#### **PROCEDURE FOR REMOTE E-VOTING AND E-VOTING DURING THE MEETING:**

19. In compliance with the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014, Regulation 44 of the SEBI Listing Regulations and Secretarial Standards for General Meetings, the equity shareholders are provided with the facility to cast their vote electronically and through the remote e-voting services provided by NSDL, on the resolution set forth in this Notice.
20. **The instructions for remote e-voting before the Meeting are as under:**

**Step 1:** Access to NSDL e-Voting system at

<https://www.evoting.nsdl.com/> How to Log-in to NSDL e-Voting website?





**A. Login method for e-Voting and joining virtual Meeting for individual shareholders holding equity shares in demat mode**

In terms of SEBI circular dated 9<sup>th</sup> December 2020 on “**e-Voting facility provided by Listed Companies**”, e-voting process has been enabled to all the individual demat account holders, by way of single login credential, through their demat accounts/websites of Depositories/DPs in order to increase the efficiency of the voting process. Individual demat account holders would be able to cast their vote without having to register again with the e-voting service provider (“ESP”) thereby not only facilitating seamless authentication but also ease and convenience of participating in e-voting process.

The equity shareholders are advised to update their mobile number and e-mail ID with their DPs in order to access e-voting facility.

Login method for individual equity shareholders holding securities in demat mode is given below:

<b>Type of equity shareholders</b>	<b>Login Method</b>
Individual equity shareholders holding securities in demat mode with NSDL.	<p><b>Users registered for NSDL IDeAS facility:</b></p> <ol style="list-style-type: none"><li>1. Visit the e-Services website of NSDL viz. <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the “<b>Beneficial Owner</b>” icon under “<b>Login</b>” which is available under ‘<b>IDeAS</b>’ section.</li><li>2. You will be prompted to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “<b>Access to e-Voting</b>” under e-Voting services and you will be able to see e-Voting page.</li><li>3. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual Meeting &amp; voting during the Meeting.</li></ol> <p><b>Users not registered for IDeAS e-Services:</b> Option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></p> <p><b>E-voting website of NSDL:</b></p> <ol style="list-style-type: none"><li>1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “<b>Login</b>” which is available under ‘<b>Shareholder /Member</b>’ section.</li></ol>

	<ol style="list-style-type: none"> <li>2. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password /OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page.</li> <li>3. Click on Company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> </ol> <p>Equity shareholders can also download NSDL Mobile App “<b>NSDL SPEED-e</b>” facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on:</p> <div style="text-align: center;">   </div> <div style="display: flex; justify-content: space-around; align-items: center;">   </div>
Individual equity shareholders holding securities in demat mode with CDSL	<p><b>Existing users who have opted for Easi /Easiest:</b></p> <ol style="list-style-type: none"> <li>1. Login through their User ID and Password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest is <a href="http://www.cdslindia.com">www.cdslindia.com</a> or <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> and click on New System My easi.</li> <li>2. After successful login of Easi /Easiest the user will be able to see the E-Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote.</li> </ol> <p><b>User not registered for Easi /Easiest:</b> Option to register is available at <a href="http://www.cdslindia.com">www.cdslindia.com</a></p> <p><b>Visit the e-Voting website of CDSL</b></p> <ol style="list-style-type: none"> <li>1. Alternatively, the user can directly access e-Voting page by providing demat account number and PAN from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered mobile &amp; e-mail as recorded in the demat account.</li> <li>2. After successful authentication, user will be provided links for the respective ESP i.e. <b>NSDL</b> where the e-Voting is in progress.</li> </ol>

Type of equity shareholders	Login Method
Individual equity shareholders (holding securities in demat mode) login through their depository participants	<ol style="list-style-type: none"> <li>Equity shareholders can also login using the login credentials of their demat account through your Depository Participant registered with NSDL /CDSL for e-Voting facility.</li> <li>Once logged in, you will be able to see e-Voting option.</li> <li>Click on e-Voting option, you will be redirected to NSDL /CDSL Depository website after successful authentication, wherein you can see e-Voting feature.</li> <li>Click on Company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> </ol>

**Important note:** Equity shareholders who are unable to retrieve User ID/Password are advised to use ‘Forget User ID’ and ‘Forget Password’ option available at abovementioned website.

Login type	Helpdesk details
Individual equity shareholders holding securities in demat mode with NSDL	Equity shareholders can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.com">evoting@nsdl.com</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30.
Individual equity shareholders holding securities in demat mode with CDSL	Equity shareholders can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 022- 23058738 or 22-23058542-43.

**B. Login Method for e-Voting and joining virtual Meeting for equity shareholders other than individual equity shareholders holding securities in demat mode and equity shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-voting website?**

- Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
- Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
- A new screen will open. You will have to enter your User ID, your Password and a Verification Code as shown on the screen.



- c. Alternatively, if you are registered for NSDL e-services i.e. IDeAS, as Step 1 you can log-in at <https://eservices.nsdl.com/> with your existing IDeAS login. Once you log-in to NSDL e-services after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. cast your vote electronically.

- a) Your User ID details are given below:

S. No.	Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a)	For equity shareholders who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example, if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b)	For equity shareholders who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example, if your Beneficiary ID is 12***** then your user ID is 12*****
c)	For equity shareholders holding shares in Physical Form.	EVEN followed by Folio Number registered with the Company For example, if folio number is 001*** and EVEN is 131959 then user ID is 131959001***

- b) Password details for equity shareholders other than individual equity shareholders are given below:

- If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- How to retrieve your 'initial password'?

- If your e-mail ID is registered in your demat account or with the Company, your 'initial password' is communicated to you on your e-mail ID. Trace the e-mail sent to you from NSDL from [evoting@nsdl.com](mailto:evoting@nsdl.com)
- Open the e-mail and open the attachment i.e. a .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

- c) If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

- Click on **"Forgot User Details /Password?"** (If you are holding shares in your demat account with NSDL or CDSL) option available on <https://www.evoting.nsdl.com/>

- (ii) Click on “**Physical User Reset Password?**” (If you are holding shares in physical mode) option available on <https://www.evoting.nsdl.com/>
- (iii) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.com](mailto:evoting@nsdl.com) mentioning your demat account number /folio number, your PAN, your name and your registered address etc.
- (iv) Equity shareholders can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
- d) After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
- e) Now, you will have to click on “Login” button.
- f) After you click on the “Login” button, Home page of e-Voting will open.

**Step 2:** Cast your vote electronically and join the Meeting on NSDL e-Voting system.

**A. How to cast your vote electronically on NSDL e-voting system?**

1. After successful login at Step 1, you will be able to see “**EVEN**” of all the companies in which you are holding shares and whose voting cycle and general meeting is in active status.
2. Select “**EVEN**” of the Company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the Meeting. For joining virtual Meeting, you need to click on “**VC/OAVM**” link placed under “**Join Meeting**”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify /modify the number of shares for which you wish to cast your vote and click on “**Submit**” and also “**Confirm**” when prompted.
5. Upon confirmation, the message “**Vote cast successfully**” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

**B. The instructions for e-Voting during the Meeting are as under:**

1. The procedure for e-Voting during the Meeting is the same as per the instructions mentioned above for remote e-Voting since the Meeting is being held through VC/OAVM.
2. The e-Voting window shall be activated upon instructions of the Chairperson during the Meeting proceedings.
3. Only those equity shareholders, who will be present in the Meeting through VC/OAVM and have not cast their vote on the resolution through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote on the resolution through e-voting system during the Meeting.

## GENERAL GUIDELINES FOR EQUITY SHAREHOLDERS:

1. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-Voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the **‘Forgot User Details/Password?’** or **‘Physical User Reset Password?’** option available on <https://www.evoting.nsdl.com/> to reset the password.
2. In case of any difficulty or queries pertaining to remote e-voting (before the Meeting and during the Meeting), you may refer to the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for equity shareholders available in the download of <https://www.evoting.nsdl.com/> or call on toll free no.: 022 - 4886 7000 or contact **Ms. Pallavi Mhatre, Senior Manager, NSDL** at [evoting@nsdl.com](mailto:evoting@nsdl.com).

## OTHER INSTRUCTIONS:

1. The equity shareholders who have cast their vote by remote e-voting prior to the Meeting may also attend /participate in the Meeting through VC/OAVM but shall not be entitled to cast their vote again.
2. Any person holding shares in physical form and non-individual equity shareholders, who becomes an equity shareholder of the Company after dispatch of the Notice of the Meeting and holding shares as of the cut-off date (as mentioned in the Notice), may obtain the login ID and password by sending a request at [evoting@nsdl.com](mailto:evoting@nsdl.com) or the Company at [investorrelations@sequent.in](mailto:investorrelations@sequent.in) or to the NSDL at <https://www.evoting.nsdl.com/>. However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using **“Forgot User Details/Password”** or **“Physical User Reset Password”** option available on <https://www.evoting.nsdl.com/> or call on toll free no. 022 - 4886 7000. In case of individual equity shareholders holding securities in demat mode becomes an equity shareholder of the Company after dispatch of the Notice of the Meeting and holding shares as of the cut-off date may follow steps mentioned in the Notice of the Meeting under **“Access to NSDL e-Voting system”**. Such equity shareholder may also view/download the Notice, Scheme, Explanatory Statement and all other documents accompanying the same from the websites of the Company, NSDL, or Stock Exchanges or obtain physical printed copy of the said Notice and accompanying documents free of charge from the Company by sending a written request to the Company Secretary at [investorrelations@sequent.in](mailto:investorrelations@sequent.in)
3. A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date can (i) join the Meeting; (ii) shall be entitled to avail the facility of remote e-voting, as well as voting at the Meeting, by following the procedure mentioned in this Notice.
4. The Scrutinizer shall, after the conclusion of voting at the Meeting, unblock and count the votes cast during the Meeting and votes cast through remote e-voting and shall make a consolidated Scrutinizer’s Report and submit the same to the Chairperson of the Meeting.



5. The result of e-voting will be declared within 2 (Two) working days from the conclusion of the Meeting and the same, along with the consolidated Scrutinizer's Report, will be placed on the website of the Company at <https://www.sequent.in>, and on the website of NSDL at <https://www.evoting.nsdl.com/> and on the website of the Stock Exchanges i.e., BSE viz. [www.bseindia.com](http://www.bseindia.com) and NSE viz. <https://www.nseindia.com/>. The Company will also display the results on the notice board at the Registered Office of the Company.

**BEFORE THE HON'BLE NATIONAL COMPANY LAW TRIBUNAL,  
HYDERABAD BENCH - II  
COMPANY APPLICATION (CAA) NO. 30/230/HDB/2025  
IN THE MATTER OF SECTIONS 230 TO 232  
AND OTHER APPLICABLE PROVISIONS  
OF THE COMPANIES ACT, 2013  
AND  
IN THE MATTER OF COMPOSITE SCHEME OF AMALGAMATION  
AMONGST  
SEQUENT SCIENTIFIC LIMITED  
(APPLICANT COMPANY 1/AMALGAMATED COMPANY)  
AND  
SYMED LABS LIMITED  
(APPLICANT COMPANY 2/TRANSFEROR COMPANY 1)  
AND  
VANDANA LIFE SCIENCES PRIVATE LIMITED  
(APPLICANT COMPANY 3/TRANSFEROR COMPANY 2)  
AND  
APPCURE LABS PRIVATE LIMITED  
(APPLICANT COMPANY 4/TRANSFEROR COMPANY 3)  
AND  
VINDHYA PHARMA (INDIA) PRIVATE LIMITED  
(APPLICANT COMPANY 5/TRANSFEROR COMPANY 4)  
AND  
S.V. LABS PRIVATE LIMITED  
(APPLICANT COMPANY 6/TRANSFEROR COMPANY 5)  
AND  
VINDHYA ORGANICS PRIVATE LIMITED  
(APPLICANT COMPANY 7/TRANSFEROR COMPANY 6)  
AND  
VIYASH LIFE SCIENCES PRIVATE LIMITED**

**(APPLICANT COMPANY 8/TRANSFEREE COMPANY 1/AMALGAMATING  
COMPANY 1)**

**AND**

**GENINN LIFE SCIENCES PRIVATE LIMITED**

**(APPLICANT COMPANY 9/TRANSFEREE COMPANY 2/TRANSFEROR  
COMPANY 7)**

**AND**

**SEQUENT RESEARCH LIMITED**

**(APPLICANT COMPANY 10/AMALGAMATING COMPANY 2)**

**AND**

**AND THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS**

**SEQUENT SCIENTIFIC LIMITED**

**(CIN: L99999TS1985PLC196357)**

A Company registered under Companies Act of 1956

Having its registered office at 3rd Floor, Srivallis Corporate,

Plot No. 290, SYN 33 34 PTO 39, Guttala Begumpet,

Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033.

**Represented by Mr. Rajaram Narayanan, Authorised Signatory**

**... Applicant Company 1/Amalgamated Company**

---

**EXPLANATORY STATEMENT UNDER SECTIONS 230 AND 232 READ WITH OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT, 2013 (“ACT”), RULE 6 OF THE COMPANIES (COMPROMISES, ARRANGEMENTS AND AMALGAMATIONS) RULES, 2016 (“CAA RULES”) AND MASTER CIRCULAR DATED 20TH JUNE 2023 BEARING REFERENCE NO. SEBI/HO/CFD/ POD-2/P/CIR/2023/93 ON COMPOSITE SCHEME OF AMALGAMATION ISSUED BY THE SECURITIES AND EXCHANGE BOARD OF INDIA TO THE NOTICE OF THE MEETING OF EQUITY SHAREHOLDERS OF SEQUENT SCIENTIFIC LIMITED CONVENED PURSUANT TO ORDER OF THE HON’BLE NATIONAL COMPANY LAW TRIBUNAL, HYDERABAD BENCH – II (“TRIBUNAL”) DATED JULY 23, 2025 (“TRIBUNAL ORDER”).**

## 1. MEETING FOR THE COMPOSITE SCHEME

- 1.1. This is a statement accompanying the Notice convening the Meeting of the equity shareholders of Sequent Scientific Limited (“**Company**”), for the purpose of their consideration and approval of the proposed Composite Scheme of Amalgamation amongst Sequent Scientific Limited (Applicant Company 1/Amalgamated Company), Symed Labs Limited (Applicant Company 2/Transferor Company 1), Vandana Life Sciences Private Limited (Applicant Company 3/Transferor Company 2), Appcure Labs Private Limited (Applicant Company 4/Transferor Company 3), Vindhya Pharma (India) Private Limited (Applicant Company 5/Transferor Company 4), S.V. Labs Private Limited (Applicant Company 6/Transferor Company 5), Vindhya Organics Private Limited (Applicant Company 7/Transferor Company 6), Viyash Life Sciences Private Limited (Applicant Company 8/Transferee Company 1/Amalgamating Company 1), Geninn Life Sciences Private Limited (Applicant Company 9/Transferee Company 2/Transferor Company 7) (the Transferor Companies 1 to 7 and the Transferee Company collectively, the “**Viyash Group Companies**”), Sequent Research Limited (Applicant Company 10/Amalgamating Company 2) and their respective shareholders and creditors (“**Composite Scheme**”) in compliance with the provisions of Sections 230 to 232 read with other applicable provisions of the Act, the circulars issued thereunder, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”).
- 1.2. The Composite Scheme also provides for various other matters consequent and incidental to the matters set out above.
- 1.3. The salient features of the Composite Scheme are set out in paragraph 5 below, and the detailed terms of the amalgamation are set out in the Composite Scheme enclosed herewith as **Annexure 1** to this Notice.
- 1.4. Capitalised terms not defined herein and used in the Notice and this Statement shall have the same meaning as ascribed to them in the Scheme.

## 2. DATE, TIME AND MODE OF MEETING

Pursuant to the Tribunal Order, the Meeting of the equity shareholders of the Company, will be held through video conferencing (“**VC**”) /other audio-visual means (“**OAVM**”) on **Saturday, August 30, 2025 at 10:00 a.m. (IST)**. The Copy of the Order dated **July 23, 2025** passed by the Hon’ble Tribunal in C.A.(CAA)/30/HYD/2025 is enclosed as **Annexure 2**.

## 3. RATIONALE AND SYNERGIES OF THE COMPOSITE SCHEME

- 3.1. SeQuent is a leading animal health pharmaceuticals company with a global footprint, presence in formulations and API segments across multiple markets and customers. Sequent has 7 (seven) state-of-the-art manufacturing facilities globally, 5 (Five) Research

and Development (R&D) centers and presence across over 100 (Hundred) markets.

- 3.2. Viyash Group Companies, together constitute an integrated, R&D & intellectual property driven global pharmaceuticals business with a strong customer base across over 150 (One Hundred Fifty) countries. Viyash has over 200 (Two Hundred) R&D scientists. Viyash has a strong focus on intellectual property with over 175 (One Hundred and Seventy-Five) filed patents and over 30 (Thirty) granted patents. The Viyash Group Companies have 9 (Nine) plants (all approved by the United States Food and Drug Administration) with end-to-end manufacturing & development capabilities.
- 3.3. The amalgamation proposed under the Composite Scheme would combine the inherent capabilities of Viyash and Sequent to create a platform with leadership in animal pharmaceuticals, end-to-end integrated capabilities across the larger global pharmaceuticals market with a strong operating and R&D backbone. The combined entity will leverage the individual businesses' strengths through the following ways:

- a) **Access to global innovator & big pharmaceuticals customers:** *The combined entity can leverage each other's' global marquee customer base with an opportunity to participate in the larger global pharmaceuticals market;*
  - b) **Leverage technical skills:** *The combined entity can leverage Viyash's strong product development, R&D, regulatory, and manufacturing capabilities to accelerate new product development and new product launches and take a wider basket of products and services to their customers.*
- 3.4. The proposed Scheme would be in the best interests of the Parties and their respective shareholders, employees, creditors, and other stakeholders as the Scheme will yield advantages as set out *inter alia* below:
- a) **Expanded marketing presence across geographies:** *The combined business will have access to a larger business development team with expertise in innovator pharmaceutical companies globally;*
  - b) **Backward integration:** *Viyash is backward integrated for multiple steps for most products and is already a qualified supplier for intermediates to SeQuent for one of the largest API that SeQuent manufactures for the US market;*
  - c) **Procurement synergies:** *Both companies have multiple common input materials (solvents, catalysts). Combined purchasing for these can reduce raw material costs & improve Gross Margins;*
  - d) **Enhanced R&D and new product pipeline:** *Viyash has over 200 (Two Hundred) R&D resources with well-equipped analytical labs. Viyash's infrastructure can deliver 15 (Fifteen) new products per year across intermediates, APIs and formulations. The combined entity will have the operating base and financial strength to accelerate investment in these areas;*
  - e) **Indirect costs:** *Multiple shared functions such as Supply Chain, Finance, HR, IT. Opportunity to improve profitability as business scales through operating leverage;*
  - f) **Scale benefits:** *Combined business to have 16 (Sixteen) manufacturing plants with 10 (Ten) US FDA approved plants and strong regulatory track record;*
  - g) **Financial strength:** *Combined business will have a more efficient capital structure with high cash flow generation and ability to incur capex for growth.*

#### 4. BACKGROUND OF THE APPLICANT COMPANIES:

##### 4.1. **Particulars of the Amalgamated Company:**

- 4.1.1. Sequent Scientific Limited (“**Amalgamated Company**”) was originally incorporated as a Public Limited company on 28<sup>th</sup> June 1985 under the provision of the Companies Act, 1956, under the name and style of “Visistha Trades and Finance Limited” under the Registrar of Companies, Mumbai. Subsequently the Amalgamated Company changed its name to “P. I. Drugs and Pharmaceuticals Limited” effective from 25<sup>th</sup> March 2004. Finally, the Amalgamated Company altered its name to “Sequent Scientific Limited” effective from 27<sup>th</sup> October 2009. The Amalgamated Company has its registered office at 3<sup>rd</sup> Floor, Srivallis Corporate, Plot No. 290, SYN 33 34 PTO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033. The Corporate Identification Number of the Amalgamated Company is L99999TS1985PLC196357. The equity shares of the Amalgamated Company are listed on the BSE Limited (“**BSE**”) and the National Stock Exchange of India Limited (“**NSE**”). BSE and NSE are hereinafter collectively referred to as “**Stock Exchanges**”.
- 4.1.2. The permanent account number of the Amalgamated Company with the income tax department is **AAACV1501G**. The e-mail address of the Amalgamated Company is **[investorrelations@sequent.in](mailto:investorrelations@sequent.in)**.
- 4.1.3. The summary of the objects of the Amalgamated Company, as per its Memorandum of Association, has been reproduced below for the perusal of the equity shareholders:
- (i) *To carry on the business of manufacturers, processors, producers, makers, Importers, exporters, buyers, sellers, suppliers, stockists, agents, merchants, distributors and concessionaries of all or any kinds of drugs, medicines, chemicals, Formulation preparation of Ectoparaciticide, Pesticides, Fungicides, Weedicides, medical plants and all types of plantations, mixtures, powder, tablets, capsules, injections, oil compounds, creams, scents, glycerine, detergent, glue, gelatin, scaps, lotions, toilet goods, pigments and all kinds of pharmaceuticals, cosmetics and medicinal goods, pigments and all kinds of pharmaceuticals, cosmetic and medical preparations required or used for beauty aid, personal hygiene or in allopathic, ayurvedic homeopath, unanl or nature cure methods or system of treatments, bandages, cotton, gauzes, crutches, stretchers and all kinds of anatomical, orthopaedic and surgical appliances and stores including prophylactics.*



- (ii) *To carry on the business as programmer, developers, consultants and developers, advisors on information /Internet system and purveyors of information services, remote processing services, software development and marketing, telecommunications support, systems and network integration and implementation and internet services and to promote encourage, establish, develop, maintain, organize, undertake, manage, operate, conduct and to run in India or abroad internet/computer training centres, data processing centres, call centres and provide computer consultancy, software consultancy, hardware consultancy and other activities through Internet and also to provide market and product service through internet, provide the solution and to set up web site and carry on e-commerce activities like manufacturing, trading, selling, marketing of various products and all sorts of services through Internet for industrial, commercial, domestic, medical, pharmaceuticals, healthcare, public utility and other general customers for various sections of society.*

Copies of the Memorandum and Articles of Association of the Company can be accessed from the following link: Shareholder Information - SeQuent

- 4.1.4. During the last five years, there has been no change in the name and objects clause of the Amalgamated Company. The registered office of the Amalgamated Company has been shifted from the State of Maharashtra to the State of Telangana with effect from 01<sup>st</sup> April 2025 .
- 4.1.5. The Amalgamated Company is one of the leading integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (APIs and finished dosage formulations) and analytical services.
- 4.1.6. The share capital of the Amalgamated Company as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorized Share Capital</b>	
40,00,00,000 equity shares of Rs. 2/- each	80,00,00,000
<b>Total</b>	<b>80,00,00,000</b>
<b>Issued Subscribed and Paid-up Share Capital</b>	
25,03,01,995 equity shares of Rs.2/- each	50,06,03,990
<b>Total</b>	<b>50,06,03,990</b>

- 4.1.7. The last annual financial statements of the Amalgamated Company have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed



herewith as **Annexure 3A**.

- 4.1.8. The details of promoters and directors of the Amalgamated Company as on date of this Notice along with their addresses are mentioned herein below:

Name	Designation/ Category	Address
CA Harbour Investments <sup>1</sup>	Promoter	GFin Corporate Services Limited, Level 6, GFin Tower, 42 Hotel Street, Cybercity, Ebene 72201, Mauritius

Sr No.	Names	Designation	DIN	Address
1.	Kamal Kishore Sharma	Director	00209430	501, Plot No. 47, Raheja Orchid Residents Association, JVPD, 9th Road, Near Punjab National Bank, Juhu, Mumbai, Maharashtra, 400049.
2.	Milind Shripad Sarwate	Director	00109854	E-201/202 Sita Vihar Near Damani Estate LBS Marg Naupada Thane, Maharashtra, 400602.
3.	Gregory John Andrews	Director	08904518	17218 W Monarch Way Surprise Arizona-85387, United States
4.	Fabian Martin Kausche	Director	08976500	10667 Poly Taylor Road, Johns Creek, Georgia, 30097, United States

---

<sup>1</sup> Classification of Promoters above is based on the definition of “Promoter” and “Promoter Group” as per SEBI Listing Regulations read with Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Sr No.	Names	Designation	DIN	Address
5.	Rajaram Narayanan	Managing Director	02977405	802, Evita Chsl Central Avenue Hiranandani Garden, Powai, Mumbai Maharashtra, 400076
6.	Neeraj Bharadwaj	Director	01314963	A-187, New Friends Colony South Delhi, Delhi, 110065.
7	Vedprakash Shantalingappa Ragate	Whole-time director	10578409	Flat No. 933, A Block, Dattathreya Enclaves Siddhartha Nagar, Kurmannapalem, Visakhapatnam, Andhra Pradesh, 530046.
8	Revati Parag Kasture	Director	07558973	101, Shree Yashraj, Rd. No. 3, Paranjape A Scheme, Ville Parle (East), Mumbai, 400057, Maharashtra.
9	Hari Babu Bodepudi	Director	01119687	Plot No,34, Sy No.38, Meenakshi Bamboos, Gachibowli, K V Ranga Reddy, Telangana, 500032.

#### 4.2. Particulars of the Transferor Company 1:

- 4.2.1. Symed Labs Limited (“**Transferor Company 1**”) was originally incorporated as a Private limited company on 17<sup>th</sup> August 1988, under provisions of the Companies Act 1956 under the name of style of “**Symed labs Private Limited**” with Registrar of Companies, Hyderabad. The Transferor Company 1 was converted from a Private Limited Company to Public Limited Company under the name “**Symed Labs Limited**” with effective from 08<sup>th</sup> June 2001. The Transferor Company 1 has its registered office at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. The Corporate Identification Number of the Transferor Company 1 is U24231TG1998PLC029961. The equity shares of the Transferor Company 1 are not listed on any stock exchange in India.
- 4.2.2. The permanent account number of the Transferor Company 1 with the income tax department is **AADCS5186M**. The e-mail address of the Transferor Company 1 is **[symed.secretarial@gmail.com](mailto:symed.secretarial@gmail.com)**.
- 4.2.3. The summary of the objects of the Transferor Company 1, as per its Memorandum of Association, have been reproduced below for the perusal of the equity

shareholders:

- (i) *To carry on the business of manufactures, buy, sell, import, export and generally deal in all types of Pharmaceuticals, Drugs and intermediaries.*
- (ii) *To carry on the research and developmental activities to develop new products and substitute for imported products for own use and for others and to develop and maintain testing house and laboratory for own use and for others.*
- (iii) *To carry on the business of Consulting Engineers in Chemicals, Pharmaceutical and Dyestuff industries.*

4.2.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 1. The registered office of the Transferor Company 1 has been changed from 8-2-293/174/3, 4<sup>th</sup> Floor, Road No.14 B. N. Reddy Colony, Banjara Hills, Hyderabad, Telangana, 500034 to Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081 with effect from 28<sup>th</sup> March 2024.

4.2.5. The Transferor Company 1 is incorporated for the purposes of dealing in all types of Pharmaceuticals, Drugs and intermediaries.

4.2.6. The share capital of the Transferor Company 1 as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorized Share Capital</b>	
20,00,000 equity shares of Rs. 10/- each	2,00,00,000
<b>Total</b>	<b>2,00,00,000</b>
<b>Issued, Subscribed and Paid-up Capital</b>	
9,30,100 equity shares of Rs. 10/- each	93,01,000
<b>Total</b>	<b>93,01,000</b>

4.2.7. The last annual financial statements of the Transferor Company 1 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3B**.

4.2.8. The details of promoters and directors of the Transferor Company 1 as on the date of the Notice along with their addresses are mentioned herein below:

Name	Category	Address
Viyash Life Sciences Private Limited <sup>2</sup>	Promoter	Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana, 500081.

Sr No.	Names	Designation	DIN	Address
1.	Hari Babu Bodepudi	Director	01119687	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.
2.	Kalidindi Srihari Raju	Director	00982034	Villa No. 59, Jayabheri The Meadows, Wipro Circle, Financial District, Gachibowli, Hyderabad, Telangana, 500032.
3.	Vijayalakshmi Vaithianathan	Director	09228935	9, Sanjeevi Nayudu Street, Thirupathiripiliyur, Cuddalore, Tamil Nadu, 607002.
4	Pradip Manilal Kanakia	Director	00770347	B-901 /1001, Salarpuria Silverwoods, Varthur Road, CV Raman Nagar, Bengaluru, Karnataka, 560093
5	Kamal Kishore Sharma	Director	00209430	501, Plot No. 47, Raheja Orchid Residents Association, JVPD, 9th Road, Near Punjab National Bank, Juhu, Mumbai, Maharashtra, 400049.
6	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.
7	Anuj Vishnukumar Poddar	Additional Director	01908009	201, Martins Nest, 9 Central Avenue, Santacruz West, Mumbai, Maharashtra, - 400054, India

#### 4.3. Particulars of Transferor Company 2:

4.3.1. Vandana Life Sciences Private Limited (“Transferor Company 2”) was

originally incorporated as a private limited company on 18<sup>th</sup> December 2002, under provisions of the Companies Act 1956 with Registrar of Companies, Hyderabad, under the name and style of “**Ahlada Pharma Private Limited**”. Subsequently with effective from 07<sup>th</sup> December 2010, the Transferor Company 2 changed its name to “**Vandana Life Sciences Private Limited**”. The Transferor Company 2 has its registered office at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. The Corporate Identification Number of the Transferor Company 2 is U24239TG2002PTC040132. The equity shares of the Transferor Company 2 are not listed on any stock exchange in India.

- 4.3.2. The permanent account number of the Transferor Company 2 with the income tax department is **AADCA9836C**. The e-mail address of the Transferor Company 2 is **dn@vindhyapharma.com**.
- 4.3.3. The summary of the objects of the Transferor Company 2, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:
- (i) *To carry on the business of processing, converting, producing, manufacturing, formulating, using, buying, acquiring, storing, packaging, selling, transporting, distributing, importing, exporting, and disposing of or otherwise dealing in all kinds of drugs, pharmaceuticals, intermediates for drugs and pharmaceuticals, alkaloids, vitamins, antibiotics, fine chemicals, hormones, medicinal, bacteriological, biological, immunological, and other chemical preparations, including sera, vaccines, and veterinary drugs.*
  - (ii) *To carry out the business of manufacturing, selling, buying, importing, exporting, distributing, stocking, or otherwise dealing in all kinds of drugs and pharmaceutical formulations, including all*

---

<sup>2</sup> including 6 nominee shareholders

*types of vitamins, antibiotics, organic and inorganic chemicals, TB drugs, anti-malarial, antidiabetic, anticancer, antifungal drugs, and other drugs. This includes all kinds of alkaloids and formulations such as tablets, liquids, capsules, injections, ointments, and their allied products, derivatives, and by-products. For this purpose, the Company may enter into technical collaborations, royalty agreements, actual user agreements, concession agreements, or any other agreements with foreign and Indian parties.*

(iii) *To carry on the business of manufacturing drugs on a loan license basis.*

- 4.3.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 2. The registered office of the Transferor has been changed from Plot no. 3, 4, 5 1<sup>st</sup> Cross Anrich Industrial Estate, IDA, Bollaram, Medak, Hyderabad, Telangana- 502325 to Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur, Rangareddi, Hyderabad, Telangana- 500081 with effect from 24<sup>th</sup> March 2021.
- 4.3.5. The Transferor Company 2 is incorporated for dealing in all kinds of drugs, pharmaceuticals, intermediates for drugs and pharmaceuticals, alkaloids, vitamins, antibiotics, fine chemicals, hormones, medicinal, bacteriological, biological, immunological, and other chemical preparations, including sera, vaccines, and veterinary drugs.
- 4.3.6. The share capital of the Transferor Company 2 as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorised Share Capital</b>	
24,00,000 Equity Shares of INR Rs. 10/- each	2,40,00,000
<b>Total</b>	<b>2,40,00,000</b>
<b>Issued Subscribed and Paid-up Share Capital</b>	
18,55,000 Equity Shares of INR Rs. 10/- each	1,85,50,000
<b>Total</b>	<b>1,85,50,000</b>

The last annual financial statements of the Transferor Company 2 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3C**.

- 4.3.7. The details of promoters and directors of the Company as on date of this Notice along with their addresses are mentioned herein below:

Name	Designation/ Category	Address
------	--------------------------	---------

	ry	
Viyash Life Sciences Private Limited <sup>3</sup>	Promoter	Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana, 500081

Sr No.	Names	Designation	DIN	Address
1.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.
2.	Kalidindi Srihari Raju	Director	00982034	Villa No. 59, Jayabheri, The Meadows, Wipro Circle, Financial District, Gachibowli, Hyderabad, Telangana, 500032.

#### 4.4. Particulars of Transferor Company 3:

- 4.4.1. Appcure Labs Private Limited (“**Transferor Company 3**”) was originally incorporated as a private limited company on 05<sup>th</sup> December 2012, under provisions of the Companies Act 1956 with Registrar of Companies, Hyderabad. The Transferor Company 3 has its registered office at 89/A, Sy. 311/5, Phase-1, Medchal, Malkajgiri, IDA Jeedimetla, Hyderabad, Telangana- 500055. The Corporate Identification Number of the Transferor Company 3 is U24232TG2012PTC084625. The equity shares of the Transferor Company 3 are not listed on any stock exchange in India.
- 4.4.2. The permanent account number of the Transferor Company 3 with the income tax department is **AALCA3391A**. The e-mail address of the Transferor Company 3 is **janaki.s@viyash.com**.

---

<sup>3</sup> including 1 nominee shareholder



- 4.4.3. The summary of the objects of the Transferor Company 3, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:
- (i) *To carry on the business of manufacture, export, import, trading of bulk drugs and intermediates, testing, analysis and quality assurance systems of various industrial, non-industrial, agricultural and other materials, such as drugs and pharmaceuticals, chemicals, fertilizers, pesticides, oils and to conduct microbiological, toxicological and bio availability studies and to render consultancy and training in all the above fields and for this purpose to establish laboratories and get the same approved by appropriate authorities..*
  - (ii) *To set up and carry on the business of manufacturing, refining, processing, preparing, acquiring, buying selling importing exporting, distributing and dealing in all kinds of medicines, remedies, chemicals, vitamins, minerals, medical herbs, disinfectants, cosmetics and toilet preparations, laboratory and scientific preparations, formulations for human, animal, poultry, aqua marine and agricultural use.*
  - (iii) *To undertake testing investigation and research and development programs relating to industries of all kinds and of all sizes including basic industries and advise on the application of existing and new processes and methods and scope of expansion of industries for the manufacture of new and varied products and for the better utilization of waste products.*
- 4.4.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 3. The registered office of the Transferor Company 3 has been changed from Plot No.2, Survey No.93, Satyam Enclave Petbasheerabad Village, Quthbullapur Mandal, Hyderabad, Telangana, 500055 to 89/A, Sy. 311/5, Phase-1, Medchal, Malkajgiri, IDA Jeedimetla, Hyderabad, Telangana, 500055 with effect from 01<sup>st</sup> December 2022.
- 4.4.5. The Transferor Company 3 is one of the leading R&D center including dealing in all types of Pharmaceuticals, Drugs and intermediaries.
- 4.4.6. The share capital of the Transferor Company 3 as on 31<sup>st</sup> March 2025 is as follows:

<b>Particulars</b>	<b>Amount (in INR)</b>
<b>Authorised Share Capital</b>	
10,00,000 Equity Shares of INR Rs. 10/- each	1,00,00,000
<b>Total</b>	<b>1,00,00,000</b>
<b>Issued Subscribed and Paid-up Share Capital</b>	
5,18,000 Equity Shares of INR Rs. 10/- each	51,80,000



<b>Total</b>	<b>51,80,000</b>
--------------	------------------

- 4.4.7. The last annual financial statements of the Transferor Company 3 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3D**.
- 4.4.8. The details of promoters and directors of the Transferor Company 3 as on date of this Notice along with their addresses are mentioned herein below:

<b>Name</b>	<b>Designation/Category</b>	<b>Address</b>
Viyash Life Sciences Private Limited <sup>4</sup>	Promoter	Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Telangana, 500081.

<b>Sr No.</b>	<b>Names</b>	<b>Designation</b>	<b>DIN</b>	<b>Address</b>
1.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.
2.	Kalidindi Srihari Raju	Director	00982034	Villa No. 59, Jayabheri, the Meadows, Wipro Circle, Financial District, Gachibowli, Hyderabad, Telangana, 500032.
3.	Hari Babu Bodepudi	Director	01119687	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.

---

<sup>4</sup> including 1 nominee shareholder

Sr No.	Names	Designation	DIN	Address
4.	Somarouthu Veeraswamy	Director	10373746	60507, Maple Block, Indu Fortune Fields Gardenia, KPHB 13TH, Phase, Kukatpally, Hyderabad, Telangana, 500072.

#### 4.5. Particulars of Transferor Company 4:

4.5.1. Vindhya Pharma (India) Private Limited (“**Transferor Company 4**”) was originally incorporated as a private limited company on 24<sup>th</sup> July 2006, under provisions of the Companies Act 1956 with Registrar of Companies, Hyderabad. The Transferor Company 4 has its registered office at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. The Corporate Identification Number of the Transferor Company 4 is U24296TG2006PTC050700. The equity shares of the Transferor Company 4 are not listed on any stock exchange in India.

4.5.2. The permanent account number of the Transferor Company 4 with the income tax department is

**AACCV4158P**. The e-mail address of the Transferor Company 4 is [janaki.s@viyash.com](mailto:janaki.s@viyash.com).

4.5.3. The summary of the objects of the Transferor Company 4, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:

- (i) *To carry on the business as buyers, sellers, importers, exporters, traders, distributors, dealers, and manufacturers, and to act as commission agents in organic and inorganic chemicals, bulk drugs, drug intermediates, pharmaceutical formulations, pesticides, dyes, and dye intermediates, as well as to provide analytical services to other industries.*
- (ii) *To establish and carry on business in India or elsewhere as a manufacturer, processor, importer, exporter, transporter, agent, broker, supplier, wholesaler, retailer, distributor, stockist, dealer, godown keeper, C&F agent, and del credere agent. This includes developing, undertaking, performing, and managing all types of job works related to bulk drugs, drug intermediates, other organic compounds, and pharmaceutical formulations, including syrups, tonics, tablets, capsules, parenterals, herbal, Ayurvedic, natural extracts, and medicinal preparations, whether on a conversion basis or otherwise.*
- (iii) *To establish, operate, organize, and manage research and*

*development facilities for the development of products and processes related to drugs, organic and inorganic intermediates, and formulations. Additionally, to buy, sell, trade, and provide research services, including analytical and process improvement services.*

- 4.5.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 4. The registered office of the Transferor Company 4 has been changed from Plot No. F11-A & F11-B (Part), Phase-I, IDA, Jeedimetla Hyderabad Telangana 500055 India to Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081 with effect from 24<sup>th</sup> March 2021.
- 4.5.5. The Transferor Company 4 is dealing with all types of pharmaceuticals, pesticides, dyes etc.
- 4.5.6. The share capital of the Transferor Company 4 as on 31<sup>st</sup> March 2025 is as follows:

<b>Particulars</b>	<b>Amount (in INR)</b>
<b>Authorised Share Capital</b>	
20,00,000 Equity Shares of Rs. 10/- each	2,00,00,000
<b>Total</b>	<b>2,00,00,000</b>
<b>Issued Subscribed and Paid-up Share Capital</b>	
18,69,982 Equity Shares of Rs. 10/- each	1,86,99,820
<b>Total</b>	<b>1,86,99,820</b>

- 4.5.7. The last annual financial statements of the Transferor Company 4 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3E**.

- 4.5.8. The details of promoters and directors of the Transferor Company 4 as on date of this Notice along with their addresses are mentioned herein below:

Sr No.	Names	Designation	DIN	Address
1.	Kalidindi Srihari Raju	Director	00982034	Villa no. 59, Jayabheri the Meadows, Wipro circle, Financial district, Gachibowli, Hyderabad, Telangana, 500032.
2.	Hari Babu Bodepudi	Director	01119687	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.
3.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.

#### 4.6. Particulars of Transferor Company 5:

- 4.6.1. **S.V. Labs Private Limited (“Transferor Company 5”)** a private limited Company, was incorporated on 10<sup>th</sup> September 2003, under the provisions of Companies Act, 1956 with the Registrar of Companies, Hyderabad. The Corporate Identification Number of the Transferor Company 5 is U24239TG2003PTC041662. The equity shares of the Transferor Company 5 are not listed on any stock exchange in India.
- 4.6.2. The Registered Office of the Transferor Company 5 is situated at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. Its permanent account number with the income tax department is **AAHCS5884J**. The e-mail address of the Transferor Company 5 is **janaki.s@viyash.com**.
- 4.6.3. The summary of the objects of the Transferor Company 5, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:
- To manufacture, sells, purchase, export, import deal in and acts as agent, distributors suppliers of chemicals used for manufacture of pharmaceuticals, drugs and enzymes. To manufacture, develop, convert sell, purchase, deal in, import, export all kinds of drugs and their by- products intermediates, derivatives, formulations and compounds.*
  - To carry on the business of manufacture, process, buy, sell, and deal in all kinds of medicines, medicinal preparations and bulk drugs, whatsoever and obtain patents for them.*

(iii) *To carry on the research with fine chemicals, drug and dry intermediaries, APIs and related activity.*

- 4.6.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 5. The registered office of the Transferor Company 5 has been changed from Plot No. 3,4 & 5, First Cross, Anrich Industrial Estate, IDA, Bollaram, Hyderabad Telangana 502325 to Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081 with effect from 22<sup>nd</sup> June 2021.
- 4.6.5. The Transferor Company 5 is one of the leading manufactures of all kinds of pharmaceuticals, drugs and enzymes etc.
- 4.6.6. The share capital of the Transferor Company 5 as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorised Share Capital</b>	
61,00,000 Equity Shares of Rs. 10/- each	6,10,00,000
2,50,00,000 Preference Share of Rs. 10/- each	25,00,00,000
<b>Total</b>	<b>31,10,00,000</b>
<b>Issued Subscribed and Paid-up Share Capital</b>	
60,38,600 Equity Shares of Rs. 10/- each	6,03,86,000
2,45,00,000 Preference shares of Rs. 10/- each	24,50,00,000
<b>Total</b>	<b>30,53,86,000</b>

- 4.6.7. The last annual financial statements of the Transferor Company 5 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3F**.

*5 including 1 nominee shareholder*

- 4.6.8. The details of promoters and directors of the Transferor Company 5 as on date of this Notice along with their addresses are mentioned herein below:

Name	Designation/Category	Address
Vindhya Pharma (India) Private Limited <sup>6</sup>	Promoter	Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081

Sr No.	Names	Designation	DIN	Address
1.	Kalidindi Srihari Raju	Director	00982034	Villa no. 59, jayabheri the meadows, wipro circle, financial district, Gachibowli, Hyderabad, Telangana, 500032.
2.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.

#### 4.7. Particulars of Transferor Company 6:

- 4.7.1. Vindhya Organics Private Limited (“Transferor Company 6”) was originally incorporated as a private limited company on 29<sup>th</sup> January 1988, under the name and style of “Parsin Chemicals Private Limited” under the provisions of Companies Act, 1956 with Registrar of Companies, Hyderabad. The Transferor Company 6 was converted from a Private Limited Company to Public Limited Company under the name “Parsin Chemicals Limited” with effect from 28<sup>th</sup> November 1988, further the name of the Transferor Company 6 was changed from Parsin Chemicals Limited to Vindhya Organics Limited with effective from 11<sup>th</sup> December 2009 and further the Transferor Company 6 was converted from a Public Limited Company to Private Limited Company under the name “Vindhya Organics Private Limited” with effect from 04<sup>th</sup> February 2010. The Corporate Identification Number of the Transferor Company 6 is U24110TG1988PTC008252. The equity shares of the Transferor Company 6 are not listed on any stock exchange in India.
- 4.7.2. The Registered Office of the Transferor Company 6 is situated at Plot No. 3,4 & 5, Anrich Industrial Estate, Bollaram, Telangana, 502325 The permanent account number of the Transferor Company 6 with the income tax department is AABCP2283Q. The e-mail address of the Transferor Company 6 is [janaki.s@viyash.com](mailto:janaki.s@viyash.com).
- 4.7.3. The summary of the objects of the Transferor Company 6, as per its Memorandum of Association, have been reproduced below for the perusal of the equity

shareholders:

- (i) *To carry on the business of manufacturing, processing, importing, exporting, running, selling, or otherwise dealing in all types of chemicals, including heavy, fine, industrial, pharmaceutical, organic, inorganic, and aromatic chemicals. This also includes fermentation products, acids, alkalis, photographic chemicals, synthetic ammonia, chromates, textile chemicals, and other chemical varieties used in various industries.*
- (ii) *To carry on the business of manufacture, process, buy, sell and deal in all kinds of medicines, medicinal preparations, and drugs, whatsoever and obtain patents for them and undertake manufacture of these items on loan license basis.*
- (iii) *To manufacture, produce, refine, prepare, import, export, purchase, sell and generally deal in all kinds of oils, oil products, oilseeds, and blends thereof. This also includes all related products, by-products, and intermediates such as fatty acids and their esters, glycerin, amines, nitrides, amides, polyamides, soaps, cosmetics, toilet preparations, emulsifiers, flotation agents, pharmaceutical preparations, animal feed, and fertilizers.*
- (iv) *To act as consulting chemists and chemical engineers, consultants in setting up of all types of chemical plants.*
- (v) *To act as dealers, distributors, and traders in all types of chemicals, including exporting them.*
- (vi) *To carry on the business of manufacturing and dealing in ION exchange resins, adhesive resins, and related raw materials.*
- (vii) *To carry on the business of tobacco processing, including curing, threshing, redrying, packing, warehousing, selling, buying, importing, and exporting. This extends to merchants, dealers, traders,*

---

<sup>6</sup> including 1 nominee equity shareholder



*buyers, and sellers of all varieties of tobacco and its products, whether manufactured or not, both within and outside India. The business also includes dealing in tobacco-related products such as cigars, pipe tobacco, white beedies, cigarettes, snuff, zarda, matchboxes, pipes, tins, canisters, snuff merchants, snuff grinders, tobacco extractions, and other related items.*

- 4.7.4. During the last five years, there has been no change in the name and objects clause of the Transferor Company 6.
- 4.7.5. The Transferor Company 6 is dealing in all kinds of pharmaceuticals, including fermentation products, acids, alkalis, photographic chemicals, synthetic ammonia, chromates and other chemical varieties used in various industries.
- 4.7.6. The share capital of the Transferor Company 6 as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorized Capital</b>	
41,00,000 Equity Shares of Rs.10/- each	4,10,00,000
<b>Total</b>	<b>4,10,00,000</b>
<b>Issued, Subscribed and Paid-up Capital</b>	
40,57,548 Equity Shares of Rs.10/- each	4,05,75,480
<b>Total</b>	<b>4,05,75,480</b>

- 4.7.7. The last annual financial statements of the Transferor Company 6 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3G**.
- 4.7.8. The details of promoters and directors of the Transferor Company 6 as on date of this Notice along with their addresses are mentioned herein below:

Name	Designation/Category	Address
Geninn Life Sciences Private Limited <sup>7</sup>	Promoter	Plot No. 3,4 & 5, Anrich Industrial Estate Bollaram, Hyderabad, Telangana - 502325

Sr No.	Names	Designation	DIN	Address
1.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.
2.	Venugopal Ghanta	Director	02713882	8/333A-302, Santhinagar, Gudivada, Krishna, Andhra Pradesh, 521301.

- 4.8. **Particulars of Transferee Company 1/Amalgamating Company 1:**

- 4.8.1. Viyash Life Sciences Private Limited (“**Transferee Company 1/Amalgamating Company 1**”) was originally incorporated as a private limited company on 21<sup>st</sup> February 2019, under the provisions of the Companies Act, 2013 with Registrar of Companies, Hyderabad. The Transferee Company 1/ Amalgamating Company 1 has its registered office at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. The Corporate Identification Number of the Transferee Company 1/Amalgamating Company 1 is U24239TG2019PTC130774. The equity shares of the Transferee Company 1/Amalgamating Company 1 are not listed on any stock exchange in India.
- 4.8.2. The Registered Office of the Transferee Company 1/Amalgamating Company 1 is situated at Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081. The permanent account number of the Transferee Company 1/Amalgamating Company 1 with the income tax department is **AAGCVE177Q**. The e-mail address of the Transferee Company 1/Amalgamating Company 1 is **janaki.s@viyash.com**.
- 4.8.3. The summary of the objects of the Transferee Company 1/Amalgamating Company 1, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:
- (i) *To manufacture, sale, purchase, deal in various pharmaceuticals products, bulk drugs, medicines, chemicals, raw materials,*
- 
- intermediates for various pharmaceutical products and to engage in business of health cares, life sciences, research and development, contract manufacturing in India and/or abroad.*

<sup>7</sup> including 1 nominee shareholder

(ii) *To manufacture, process, produce, assemble, distribute, buy, sell, import, export and deal in pharmaceuticals, drugs, chemicals, medicines, raw materials, intermediates, vaccines, tonics, enzymes, steroids, vitamins, hormones, antibiotics, antiseptics, disinfectants, veterinary medicines, poultry medicines, herbal products, their by-products, intermediates, residues, mixtures, compounds, preparations, cosmetics, pesticides, medicinal components, injections, dye wares, cordials, liquors, restoratives, acids, surgical preparations, medical equipment's, surgical equipment's and other related equipment's, used in all therapies of medical treatment and the other lifesaving equipment's apparatus and medicinal equipment's and to engage in the business of Healthcare, life sciences, research and development, contract manufacturing etc. in India and/or abroad.*

- 4.8.4. During the last five years, there has been no change in the name and objects clause of the Transferee Company 1/Amalgamating Company 1. The registered office of the Transferee Company 1/Amalgamating Company 1 has been changed from Plot No 34 SY NO 30/P 38/P 39/P Gachibowli Kondapur, Hyderabad-500032, Telangana to Plot No. 290, Srivallis Corporate, Road No. 6, Kakatiya Hills, Madhapur, Hyderabad, Shaikpet, Telangana, 500081 with effect from 07<sup>th</sup> March 2020.
- 4.8.5. The Transferee Company 1/Amalgamating Company 1 is one of the leading dealers of various pharmaceuticals products and to engaged in the business of health cares, life sciences, research and development contract manufacturing.
- 4.8.6. The share capital of the Transferee Company 1/Amalgamating Company 1 as on 31<sup>st</sup> March 2025 is as follows:

Particulars	Amount (in INR)
<b>Authorized Share Capital</b>	
46,52,52,000 equity shares of Rs. 10/- each	4,65,25,20,000
20,34,95,000 preference shares of Rs. 10/- each <sup>8</sup>	2,03,49,50,000
1,00,00,000 preference shares of Rs. 90/- each <sup>9</sup>	90,00,00,000
<b>Total</b>	<b>7,58,74,70,000</b>
<b>Issued, subscribed and fully Paid-up Share Capital</b>	
31,57,73,941 equity shares of Rs. 10/- each	3,15,77,39,410
1,86,15,406 Equity shares of Rs. 10/- each <sup>10</sup>	18,61,54,060
<b>Total</b>	<b>334,38,93,470</b>

The last annual financial statements of the Transferee Company 1/Amalgamating Company 1 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3H**.

- 4.8.7. The details of promoters and directors of the Transferee Company 1/Amalgamating Company 1 as on date of this Notice along with their addresses are mentioned herein below:

Sr No.	Name	Designation/Category	Address
1.	CA Hull Investments (Equity)	Promoter	Lot 15 A3, First Floor, Cyber City, Ebene 72201, Mauritius.
2.	Dr. Hari Babu Bodepudi	Promoter	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.
3.	Dr. Srihari Raju Kalidindi	Promoter	Villa no. 59, jayabheri the meadows, wipro circle, financial district, Gachibowli, Hyderabad, Telangana, 500032.
4.	Vijaya Bodepudi	Promoter group	Plot No.34, Meenakshi Bamboos, Sy No.38P, Gachibowli, K.V. Rangareddy Gachibowli, Telangana, 500032.
5.	Dr. Latha Swarna Kalidindi	Promoter group	Villa No.59, Jayabheri, The Meadows, Financial District, Gachibowli, Besides Q City, Near Wipro Circle, Gachibowli, K.V. Ranga Reddy, Telangana, 500032.

---

<sup>8</sup> CCPS Series A2

<sup>9</sup> CCPS Series B

<sup>10</sup> Class B (84,30,550 Shares), Class C1 (65,29,469 Shares) & Class C2 (36,55,387 Shares)

<b>Sr No.</b>	<b>Name</b>	<b>Designation/Category</b>	<b>Address</b>
6.	Barclays wealth trustees (India) private limited as Trustee of Rajkamal Family Trust	Promoter group	Nirlon knowledge park, 9 <sup>th</sup> floor, Block B-6, Off. western Express Highway, Goregaon (east), Mumbai, 400063, Maharashtra.
7.	Veeramachaneni Sirisha	Promoter group	H.No. 5-45, beside Bundar Road, kottur, Kakainada, Edupugallu, Andhra Pradesh, 521151.
8.	Bodepudi V L S Kumari	Promoter group	G-3, Venu Apartments, Sitaram Nagar, Patamata lanka, Vijayawada-10, NTR Zilla, Andhra Pradesh.
9.	Vijaya Durga Chintalapati	Promoter group	12-13-705/10/AAND B F 103 Balaji Residency, Gokul Nagar, Tarnaka, Hyderabad, 500017, Telangana.
10.	Kota Krishnarao	Promoter group	Plot No.34, Sy No.38, Meenakshi Bamboos, Gachibowli, K.V Rangareddy Gachibowli, Telangana, 500032.

<b>Sr No.</b>	<b>Names</b>	<b>Designation</b>	<b>DIN</b>	<b>Address</b>
1.	Hari Babu Bodepudi	Whole-time director	01119687	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.
2.	Gurveen Singh	Director	09507365	M-59, Greater Kailash, Part I, New Delhi, South Delhi, Delhi, 110048.
3.	Amit Jain	Nominee Director	06917608	E-603, Raheja Vivarea, Dr. A L Nair Marg, Near Jacob Circle, Mahalaxmi, Mumbai, Maharashtra, 400011.
4.	Kalidindi Srihari Raju	Whole-time director	00982034	Villa No. 59, Jayabheri, The Meadows, Wipro Circle, Financial District, Gachibowli, Hyderabad, Telangana, 500032.
5.	Pradip Manilal Kanakia	Director	00770347	B-901 /1001 Salarpuria Silverwoods Varthur Road, Cv Raman Nagar, Bengaluru Karnataka, 560093.

6.	Kamal Kishore Sharma	Director	00209430	501, Plot No. 47, Raheja Orchid Residents Association, JVPD, 9th Road, Near Punjab National Bank, Juhu, Mumbai, Maharashtra, 400049.
7.	Sunil Kaul	Nominee Director	05102910	29-09, Park Infinia, 2A Lincoln Road, Singapore, 308364.
8.	Anuj Vishnukumar Poddar	Additional Director	01908009	201, Martins Nest, 9 Central Avenue, Santacruz West, Mumbai, Maharashtra, 400054.

#### 4.9. Particulars of Transferee Company 2/Transferor Company 7:

- 4.9.1. Genin Life Sciences Private Limited (“**Transferee Company 2/Transferor Company 7**”) was originally incorporated as a private limited company on 31<sup>st</sup> October 2019, under provisions of the Companies Act, 2013 with Registrar of Companies, Hyderabad. The Transferee Company 2/Transferor Company 7 has its registered office at Plot No. 3, 4 & 5, Anrich Industrial Estate, Bollaram, Medak, Hyderabad, Telangana, 502325. The Corporate Identification Number of the Transferee Company 2/Transferor Company 7 is U24299TG2019PTC136520. The equity shares of the Transferee Company 2/Transferor Company 7 are not listed on any recognized stock exchange in India.
- 4.9.2. The permanent account number of the Transferee Company 2/Transferor Company 7 with the income tax department is **AAICG0570A**. The e-mail address of the Transferee Company 2/Transferor Company 7 is **janaki.s@vivash.com**.
- 4.9.3. The summary of the objects of the Transferee Company 2/Transferor Company 7, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:

- (i) *To manufacture, sale, purchase, deal in various pharmaceuticals products, bulk drugs, medicines, chemicals, raw materials, intermediates for various pharmaceutical products and to engage in business of health cares, life sciences, research and development, contract manufacturing in India and/or abroad.*
- (ii) *To manufacture, process, produce, assemble, distribute, buy, sell, import, export and deal in pharmaceuticals, drugs, chemicals, medicines, raw materials, intermediates, vaccines, tonics, enzymes, steroids, vitamins, hormones, antibiotics, antiseptics, disinfectants, veterinary medicines, poultry medicines, herbal products, their by-products, intermediates, residues, mixtures, compounds, preparations, cosmetics, pesticides, medicinal components, injections, dye wares, cordials, liquors, restoratives, acids, surgical preparations, medical equipments, surgical equipments and other related equipments, used in all therapies of medical treatment and the other lifesaving equipments apparatus and medicinal equipments and to engage in the business of Healthcare, life sciences, research and development, contract manufacturing etc. in India and/or abroad.*
- 4.9.4. During the last five years, there has been no change in the name and objects clause of the Transferee Company 2/Transferor Company 7.
- 4.9.5. The Transferee Company 2/Transferor Company 7 is incorporated for the purposes dealing in various pharmaceuticals products and to engaged in the business of health cares, life sciences, research and development contract manufacturing.
- 4.9.6. The share capital of the Transferee Company 2/Transferor Company 7 as on 31<sup>st</sup> March 2025 is as follows:

<b>Particulars</b>	<b>Amount (in INR)</b>
<b>Authorized Share Capital</b>	
1,00,000 equity shares of Rs. 10/- each	10,00,000
<b>Total</b>	<b>10,00,000</b>
<b>Issued, subscribed and Paid-up Share Capital</b>	
1,00,000 equity shares of Rs. 10/- each	10,00,000
<b>Total</b>	<b>10,00,000</b>

The last annual financial statements of the Transferee Company 2/Transferor Company 7 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3I**.

- 4.9.7. The details of promoters and directors of the Transferee Company 2/Transferor Company 7 as on date of this Notice along with their addresses are mentioned



herein below:

<b>Sr No.</b>	<b>Name</b>	<b>Designation/Category</b>	<b>Address</b>
1.	Dr. Hari Babu Bodepudi	Promoter	Plot No-34, Sy No-38, Meenakshi Bamboos, Gachibowli, K V Rangareddy, Telangana, 500032.
2.	Dr. Kalidindi Srihari Raju	Promoter	Villa no. 59, jayabheri the meadows, wipro circle, financial district, Gachibowli, Hyderabad, Telangana, 500032.
3.	Vijaya Bodepudi	Promoter group	Plot No.34, Meenakshi Bamboos, Sy No.38P, Gachibowli, K.V. rangareddy Gachibowli, Telangana, 500032.
4.	Latha Swarna Kalidindi	Promoter group	Villa No.59, Jayabheri, The Meadows, Financial District, Gachibowli, Besides Q City, Near Wipro Circle, Gachibowli, K.V. Ranga Reddy, Telangana, 500032.
5.	Vijaya Durga Chintalapati	Promoter group	12-13-705/10/AAND B F 103 Balaji Residency, Gokul Nagar, Tarnaka, Hyderabad, 500017, Telangana.

<b>Sr No.</b>	<b>Names</b>	<b>Designation</b>	<b>DIN</b>	<b>Address</b>
1.	Venugopal Ghanta	Director	02713882	Gudivada, Krishna, Andhra Pradesh, 521301.
2.	Srinivas Vasireddy	Director	09771153	Villa No. 84, Vasantha City, Tirumalagiri, Telangana, 500049.

#### 4.10. Particulars of Amalgamating Company 2:

- 4.10.1. Sequent Research Limited (“**Amalgamating Company 2**”) was originally incorporated as a private limited company on 13<sup>th</sup> April 2007, under the provisions of the Companies Act, 1956 with Registrar of Companies, Karnataka. With Effect from 18<sup>th</sup> March 2008, the Amalgamating Company 2 had changed its name to “Sequent Research Limited”, consequent to the conversion of the Amalgamating Company 2 to Public Limited. The Amalgamating Company 2 has its registered office at 3<sup>rd</sup> Floor, Srivalli s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India, 500033. The Corporate Identification Number of the Amalgamating Company 2 is U24232TS2007PLC196886. The equity shares of the Amalgamating Company 2 are not listed on any stock exchange in India.
- 4.10.2. The permanent account number of the Amalgamating Company 2 with the income tax department is **AAKCS7538Q**. The e-mail address of the Amalgamating Company 2 is **investorrelations@sequent.in**.
- 4.10.3. The summary of the objects of the Amalgamating Company 2, as per its Memorandum of Association, have been reproduced below for the perusal of the equity shareholders:
  - (i) *To carry on the business of research and manufacturing of all kinds of chemicals, synthetic chemicals, elements, chemical compounds, biological, bacteriological, bio-chemicals, therapeutic, and pharmaceutical products, as well as medicinal formulations and other related preparations, in India or elsewhere.*
  - (ii) *To engage in the sale or other commercial transactions involving formulas and formulations for the manufacture of pharmaceutical drugs and medicines. This includes injections, capsules, lotions, patent and proprietary medicines, common medicinal preparations, elixirs, drops, tonics, liquid drugs, injections, tablets, lotions, ointments, antibiotics, hormones, liver extracts, and pharmaceutical products in both biological and non-biological forms. It also covers tranquilizers, vitamins, tonic preparations, medicated ointments, hormone preparations, ayurvedic products, medicated powders, pre-packed drugs, analgesics, antipyretic preparations, anti-diarrheal preparations, anti-cholinergic preparations, anti-asthmatic preparations, ophthalmic lotions and ointments, and all other drug- related products as defined under the Drugs Act and Rules.*

- (iii) *To manufacture antibiotics, alkaloids, drug extracts, and other preparations useful for human and veterinary use. This also includes pesticides and plant protection products against pathogenic bacteria, fungi, protozoa, viruses, and other microorganisms, using chemical, physical, fermentation, bacteriological, or other methods, either independently, in collaboration with others, or under license.*
- (iv) *To operate as manufacturers, producers, formulators, exporters, sellers, importers, distributors, merchants, traders, and dealers in proprietary medicines, common medical preparations, drugs, chemicals, allied solvents, dyes, vitamin preparations, elixirs, drops, tonics, liquid drugs and medicines, injections, tablets, capsules, lotions, and ointments in India or elsewhere.*
- 4.10.4. During the last five years, there has been no change in the name and objects clause of the Amalgamating Company 2. The registered office of the Amalgamating Company 2 has been changed from 09<sup>th</sup> April 2025.
- 4.10.5. The Amalgamating Company 2 is a leading contract research organization that specializes in analytical and bio analytical services to support the API, pharmaceutical, personal care, institutional and nutraceutical companies.
- 4.10.6. The share capital of the Amalgamating Company 2 as on 31<sup>st</sup> March 2025 is as follows:

<b>Particulars</b>	<b>Amount (in INR)</b>
<b>Authorized Share Capital</b>	<b>Amount (INR)</b>
47,00,000 equity shares of Rs.10/- each	4,70,00,000
<b>Total</b>	<b>4,70,00,000</b>
<b>Issued, subscribed and Paid-up share capital</b>	<b>Amount (Rs.)</b>
44,10,000 equity shares of Rs.10/- each	4,41,00,000
<b>Total</b>	<b>4,41,00,000</b>

- 4.10.7. The last annual financial statements of the Amalgamating Company 2 have been audited for the financial year ended 31<sup>st</sup> March 2025, which are enclosed herewith as **Annexure 3J**.

- 4.10.8. The details of promoters and directors of the Amalgamating Company 2 as on date of this Notice along with their addresses are mentioned herein below:

Name	Designation/ Category	Address
Sequent Scientific Limited <sup>11</sup>	Promoter	3 <sup>rd</sup> Floor, Srivallis Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033.

Sr No.	Names	Designation	DIN	Address
1.	Rajaram Narayanan	Director	02977405	802, Evita CHS, Central Avenue, Hiranandani Garden, Powai, Mumbai-400076 Maharashtra.
2.	Prasad Sitaram Lad	Director	09597006	Flat No. 50, 2 <sup>nd</sup> Floor, Suchitra Building Ghantali Road, Behind Ghantali Mandir, Naupada, Thane, Maharashtra, 400602.
3.	Vedprakash Shantalingappa Ragate	Director	10578409	Flat No. 933, A Block, Dattathreya Enclaves Siddharatha Nagar, Kurmannapalem, Visakhapatnam, Andhra Pradesh, 530046.
4.	Saurav Bhala	Director	10490964	Flat No. 1701, Athene-B, Lodha Paradise, Majiwada, Eastern Express Highway, Thane, 400601, Maharashtra.

## 5. SALIENT FEATURES OF THE SCHEME

- 5.1. The salient features of the Composite Scheme are, *inter-alia*, as stated below. The capitalized terms used herein shall have the same meaning as ascribed to them in Clause 1 of Part I of the Composite Scheme.
- 5.2. The Composite Scheme provides for the following:
- 5.2.1. reduction of share capital of the Transferee Company 1 by cancelling the partly paid-up equity shares of the Transferee Company 1;
- 5.2.2. amalgamation of the Transferor Company 1, Transferor Company 2, Transferor Company 3, Transferor Company 4 and Transferor Company 5 (collectively referred to hereinafter as “**Transferor Companies**”) with the Transferee

Company 1 with effect from the Appointed Date, in accordance with the provisions of Section 2(1B) and other relevant provisions of the Income Tax Act and consequent dissolution of the Transferor Companies without being wound up;

- 5.2.3. amalgamation of the Transferor Company 6 with the Transferee Company 2 with effect from the Appointed Date, in accordance with the provisions of Section 2(1B) and other relevant provisions of the Income Tax Act and consequent dissolution of the Transferor Company 6 without being wound up;
- 5.2.4. amalgamation of the Transferor Company 7 with Transferee Company 1 with effect from the Appointed Date, in accordance with the provisions of Section 2(1B) and other relevant provisions of the Income Tax Act and consequent dissolution of Transferor Company 7 without being wound up, and the issuance of Merger Consideration Shares 1 to the equity shareholders of the Transferor Company 7 in accordance with Share Exchange Ratio 1;
- 5.2.5. amalgamation of the Amalgamating Company 1 and Amalgamating Company 2 (collectively referred to hereinafter as “**Amalgamating Companies**”) with the Amalgamated Company with effect from the Appointed Date, in accordance with the provisions of Section 2(1B) and other relevant provisions of the Income Tax Act and consequent dissolution of the Amalgamating Companies without being wound up, and the issuance of Merger Consideration Shares 2 to the equity shareholders of the Amalgamating Company 1 in accordance with Share Exchange Ratio 2, and the issuance of Amalgamated Company Warrants to the share warrant holders in Amalgamating Company 1 in accordance with Warrant Exchange Ratio; and

---

*11 including 6 nominee shareholders*

- 5.2.6. various other matters consequent and incidental to the matters set out above.
- 5.2.7. **“Appointed Date” means 01<sup>st</sup> April 2025;**
- 5.2.8. **“Effective Date 1”** means the last of the dates on which following events shall have taken place: (i) approvals or events specified in Clauses 74.1.1 to 74.1.6 of the Scheme are satisfied or have occurred or obtained or the requirement of which have been waived (in writing) in accordance with this Scheme, and (ii) filing of certified copies of Sanction Order by relevant Parties for Part II to Part V of this Scheme; References in this Scheme to the date of “coming into effect of this Scheme” or “upon the Scheme becoming effective” or “upon effectiveness of Part II /Part III/Part IV/Part V of the Scheme” or “upon effectiveness of Part II /Part III/Part IV/Part V of this Scheme” or “upon Part II /Part III/Part IV /Part V of this Scheme becoming effective” or “Part II Part III/Part IV/ Part V of the Scheme coming into effect” shall mean the Effective Date 1;.
- 5.2.9. **“Effective Date 2”** means the last of the dates on which the certified copies of Sanction Order are filed by the Amalgamating Companies and the Amalgamated Company with the RoC in respect of Part VI of this Scheme, which shall be a date after receipt by the Amalgamated Company of a list of shareholders of the Amalgamating Company 1 upon completion of allotment of Merger Consideration Shares 1; References in this Scheme to the date of “coming into effect of this Scheme” or “upon the Scheme becoming effective” or “upon effectiveness of Part VI of the Scheme” or “upon effectiveness of Part VI of this Scheme” or “upon Part VI of this Scheme becoming effective” or “Part VI of the Scheme coming into effect” shall mean the Effective Date 2;
- 5.2.10. The Composite Scheme shall become effective from the Appointed Date but shall become operative from the Effective Date.
- 5.2.11. Consideration as Part of Composite Scheme:
- a) **Consideration for merger of Transferor Companies with Transferee Company 1:**  
 Since the Transferor Companies are wholly owned, either directly or indirectly, by Transferee Company 1, no shares shall be issued as consideration for the amalgamation. Upon the Composite Scheme becoming effective, all shares held by Transferee Company 1 (including those held through its nominees) in the Transferor Companies shall stand cancelled without any issuance of new shares.
  - b) **Consideration for merger of Transferor Company 6 with Transferee Company 2:**  
 Since Transferor Company 6 is a wholly owned subsidiary of Transferee Company 2, and Transferee Company 2, being the holding company, cannot

issue or allot shares to itself, no shares shall be issued as consideration for the amalgamation. Accordingly, all shares of Transferor Company 6 held by Transferee Company 2, including those held through its nominees, along with the related investment as recorded in the books of Transferee Company 2, shall stand cancelled upon Part IV of the Composite Scheme becoming effective, without any issuance or allotment of new shares.

c) **Consideration for merger of Transferor Company 7 with Transferee Company 1:**

Upon Part V of the Composite Scheme becoming effective and in consideration of the amalgamation of the Transferor Company 7 into the Transferee Company 1, the Transferee Company 1 shall, without any further application, act or deed, issue and allot to the Eligible Shareholders 1 (as defined in the Composite Scheme) in the following ratio:

***“47 (Forty-Seven) equity shares of the Transferee Company 1, credited as fully paid-up equity shares of the face value of INR 10 (Rupees Ten only) each, for every 1 (One) fully paid-up equity shares of INR 10 (Rupees Ten only) each held by such member in the Transferor Company 7. (Share Exchange Ratio 1).”***

d) **Consideration for merger of Amalgamating Company 1 with the Amalgamated Company: Equity Shareholder:**

Upon Part VI of the Composite Scheme becoming effective and in consideration of the amalgamation of the Amalgamating Company 1 into the Amalgamated Company, the



Amalgamated Company shall, without any further application, act or deed, issue and allot for the Eligible Shareholders 2 in the following ratio:

***“56 (Fifty-Six) equity shares of the Amalgamated Company, credited as fully paid-up equity shares of the face value of INR 2 (Rupees Two only) each, for every 100 (One Hundred) fully paid- up equity shares of INR 10 (Rupees Ten only) each held by such member in the Amalgamating Company 1. (Share Exchange Ratio 2)”***

**Warrants Holders:**

Additionally, upon Part VI of the Composite Scheme becoming effective and in consideration of the amalgamation of the Amalgamating Company 1 into the Amalgamated Company, the Amalgamated Company shall pursuant to this Composite Scheme, and as an integral part hereof, without any further application, act or deed, issue and allot, in demat form, to the Warrant Holders (as defined in the Composite Scheme) in the following ratio

***“56 (Fifty-Six) share warrants of the Amalgamated Company (at the Warrant Price (defined below) for every 100 (One Hundred) share warrants of the Amalgamating Company 1.” (“Warrant Exchange Ratio”)***

*The Amalgamated Company Warrants shall be issued in accordance with the SEBI ICDR Regulations and the SEBI Preferential Allotment Circular (“Warrant Price”) and is INR 181.94 per Amalgamated Company Warrant.*

**e) Consideration for merger of Amalgamating Company 2 with the Amalgamated Company:**

Since the Amalgamating Company 2 is a wholly owned subsidiary of the Amalgamated Company, and the Amalgamated Company, being the holding company, cannot issue or allot any shares to itself, no shares whatsoever shall be issued by the Amalgamated Company in consideration of the amalgamation. Accordingly, all such shares of the Amalgamating Company 2 held by the Amalgamated Company along with its nominees and the investment of the Amalgamated Company in such shares as appearing in the books of the Amalgamated Company shall stand cancelled upon Part VI of the Scheme becoming effective without issue or allotment of new shares in lieu of shares of the Amalgamating Company 2.

- 5.2.12. The equity shares of the Amalgamated Company will subsequently be listed on BSE Limited and the National Stock Exchange of India Limited.

**Note:** *The above details are the salient features of the Composite Scheme. The equity shareholders are requested to read the entire text of the Composite Scheme annexed hereto to get fully acquainted with the provisions thereof.*

## **6. RELATIONSHIP SUBSISTING BETWEEN PARTIES TO THE COMPOSITE SCHEME**

The Amalgamating Company 2 is a wholly owned subsidiary of Amalgamated Company. As on 31<sup>st</sup> March 2025, Amalgamated Company holds 44,10,000 equity shares of Rs.10/- each of the Amalgamating Company 2 representing 100% of its share capital.

The Transferor Company 1, Transferor Company 2, Transferor Company 3, Transferor Company 4 and Transferor Company 5 are directly or indirectly wholly owned subsidiary companies of Transferee Company 1/Amalgamating Company 1. Transferor Company 6 is wholly owned subsidiary company of Transferee Company 2/Transferor Company

7. As on 31<sup>st</sup> March 2025, Transferee Company 1/Amalgamating Company 1 holds directly 9,30,100 equity shares of Rs.10/- each of the Transferor Company 1 representing 100% of its share capital. Transferee Company 1/Amalgamating Company 1 holds directly 18,55,000 equity shares of Rs.10/- each of the Transferor Company 2 representing 100% of its share capital. Transferee Company 1/Amalgamating Company 1 holds directly 5,18,000 equity shares of Rs.10/- each of the Transferor Company 3 representing 100% of its share capital. Transferee Company 1/Amalgamating Company 1 holds directly 18,69,982 equity shares of Rs.10/- each of the Transferor Company 4 representing 100% of its share capital. Transferee Company 1/Amalgamating Company 1 holds indirectly 60,38,590 equity shares of Rs.10/- each of the Transferor Company 5 representing 100% of its share capital. Transferee Company 2/Transferor Company 7 holds 40,57,548 equity shares of Rs.10/- each of the Transferor Company 6 representing 100% of its share capital.

Further the shareholders of Transferee Company 2/Transferor Company 7 are a subset of the shareholders of Transferee Company 1/Amalgamating Company 1. Additionally, the promoter of the Amalgamated Company and the controlling shareholder of Transferee Company 1/Amalgamating Company 1, are under common control.

## 7. BOARD APPROVALS

- 7.1. The Board of Directors of the Amalgamated Company at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour / against / did not participate or vote</b>
Dr. Kamal Sharma	<b>Voted in favour</b>
Mr. Milind Sarwate	<b>Voted in favour</b>
Dr. Kausalya Santhanam	<b>Voted in favour</b>
Mr. Neeraj Bharadwaj	<b>Voted in favour</b>
Dr. Fabian Kausche	<b>Voted in favour</b>
Mr. Gregory Andrews	<b>Voted in favour</b>
Mr. Rajaram Narayanan	<b>Voted in favour</b>
Mr. Vedprakash Ragate	<b>Voted in favour</b>
Dr. Hari Babu Bodepudi	<b>Did not participate or vote</b>

- 7.2. The Board of Directors of the Transferor Company 1 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against / did not participate or vote</b>
Dr. Hari Babu Bodepudi	<b>Voted in favour</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Pradip Manilal Kanakia	<b>Voted in favour</b>
Dr. Kamal Kishore Sharma	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.3. The Board of Directors of the Transferor Company 2 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against / did not participate or vote</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.4. The Board of Directors of the Transferor Company 3 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against /did not participate or vote</b>
Dr. Hari Babu Bodepudi	<b>Voted in favour</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.5. The Board of Directors of the Transferor Company 4 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against /did not participate or vote</b>
Dr. Hari Babu Bodepudi	<b>Voted in favour</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.6. The Board of Directors of the Transferor Company 5 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against /did not participate or vote</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.7. The Board of Directors of the Transferor Company 6 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against /did not participate or vote</b>
Mr. Venugopal Ghanta	<b>Voted in favour</b>
Mr. Srinivas Vasireddy	<b>Voted in favour</b>

- 7.8. The Board of Directors of the Transferee Company 1/Amalgamating Company 1 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

<b>Name of Director</b>	<b>Voted in favour /against /did not participate or vote</b>
Dr. Hari Babu Bodepudi	<b>Voted in favour</b>
Dr. Kalidindi Srihari Raju	<b>Voted in favour</b>
Mr. Pradip Manilal Kanakia	<b>Voted in favour</b>
Dr. Kamal Kishore Sharma	<b>Voted in favour</b>
Ms. Gurveen Singh	<b>Voted in favour</b>
Mr. Amit Jain	<b>Voted in favour</b>
Mr. Sunil Kaul	<b>Voted in favour</b>
Mr. Anuj Vishnukumar Poddar	<b>Voted in favour</b>

- 7.9. The Board of Directors of the Transferee Company 2/Transferor Company 7 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

Name of Director	Voted in favour /against /did not participate or vote
Mr. Venugopal Ghanta	Voted in favour
Mr. Srinivas Vasireddy	Voted in favour

- 7.10. The Board of Directors of the Amalgamating Company 2 at its Meeting held on 26<sup>th</sup> September 2024 unanimously approved the Composite Scheme, as detailed below:

Name of Director	Voted in favour /against / did not participate or vote
Mr. Rajaram Narayanan	Voted in favor
Mr. Prasad Sitaram Lad	Voted in favor
Mr. Vedprakash Ragate	Voted in favor
Mr. Saurav Bhala	Voted in favor

#### 8. **INTEREST OF DIRECTORS, KEY MANAGERIAL PERSONNEL (KMPs) AND THEIR RELATIVES**

Other than as set out below, none of the Directors, KMPs (as defined under the Act and rules framed thereunder) of the Applicant Companies and their respective relatives (as defined under the Act and rules framed thereunder) have any interest in the Composite Scheme except to the extent of their shareholding in the Applicant Companies, if any.

Dr. Srihari Raju Kalidindi and Dr. Hari Babu Bodepudi, directors of the Amalgamating Company 1, and their respective relatives, hold certain equity shares and/or warrants of the Amalgamating Company 1, and accordingly will be entitled to receive equity shares and/or warrants, as applicable, of the Amalgamated Company as per the relevant exchange ratio determined under the Valuation Report, pursuant to the effectiveness of the Scheme.

The details of the shareholding of the directors, KMPs and their relatives of each the Applicant Companies are enclosed herewith as **Annexure 4**.

Further, Dr. Hari Babu Bodepudi, a non-executive non-independent director of the Amalgamated Company, is entitled, as per the terms of his existing employment agreement with Amalgamating Company 1, to receive a cash bonus upon occurrence of certain identified events, which would include a merger involving Amalgamating Company 1.

## 9. EFFECT OF SCHEME ON STAKEHOLDERS

The effect of the Composite Scheme on various stakeholders is summarised below:

### 9.1. Shareholders, KMPs, Promoter and Non-Promoter Shareholders

The effect of the Composite Scheme on the shareholders, KMPs, Promoter and Non-Promoter shareholders of all the Applicant Companies are given in the reports adopted by the respective Board of Directors of the Applicant Companies at their respective meetings held on 26<sup>th</sup> September 2024 pursuant to the provisions of Section 232(2)(c) of the Act are enclosed herewith as **Annexure 5A** and **5J** respectively.

### 9.2. Directors

9.2.1. The directors of the Amalgamated Company or their relatives do not have any interest in the Composite Scheme, financially or otherwise, except to the extent disclosed in paragraph 8 above, and except as shareholders or employees of the Amalgamated Company, where applicable. The interests of the directors of the Amalgamated Company are not adversely affected on account of the Composite Scheme.

9.2.2. It is clarified that the composition of the Board of Directors of all the Applicant Companies may change by appointments, retirements or resignations in accordance with the provisions of the Act, SEBI Listing Regulations and Memorandum and Articles of Association of the Company as may be applicable but the Scheme itself does not affect the office of the directors of the Applicant Companies.

9.2.3. The effect of the Composite Scheme on the Directors of the Applicant Companies in their capacity as shareholders of such companies are the same as in case of other shareholders of such company, as mentioned in the aforesaid reports are enclosed as Annexure 4 and 5 respectively above.

### 9.3. Employees

9.3.1. Upon effectiveness of the Composite Scheme, all employees of the Transferor Companies and Amalgamating Companies who are in employment as on the Effective Date 2, shall become the employees of the Amalgamated Company, without any break or interruption in their services, on terms and conditions no less favorable than those that were applicable to such employees immediately prior to such amalgamation, with the benefit of continuity of service without any interruption in service.

9.3.2. The Composite Scheme will have no effect on the existing employees of the Amalgamated Company.

### 9.4. Creditors

9.4.1. Under the Composite Scheme, no arrangement or compromise is being proposed with the creditors (secured or unsecured) of the Amalgamated Company or any of the Transferor Companies and Amalgamating Companies. The liability of the creditors of the Amalgamated Company and



each of the Transferor Companies and each of the Amalgamating Companies, under the Composite Scheme, is neither being reduced nor being extinguished.

- 9.4.2. Upon effectiveness of the Composite Scheme, the creditors of the Amalgamated Company will continue to be creditors of the Amalgamated Company and the creditors of each of the Transferor Companies and each of the Amalgamating Companies will become the creditors of the Amalgamated Company pursuant to the Composite Scheme, on the same terms and conditions, as before.

9.5. **Debenture holders and Debenture Trustees**

The Amalgamated Company, each of the Transferor Companies and each of the Amalgamating Companies have not issued any debentures, therefore there are no debenture holders and, the requirement of appointing a debenture trustee does not arise.

9.6. **Depositors and Deposit Trustees**

The Amalgamated Company and each of the Amalgamating Companies have not accepted any deposits within the meaning of the Act and rules framed thereunder. Hence, no deposit trustees have been appointed by the said companies.

- 9.7. There will be no adverse effect on account of the Composite Scheme on the aforesaid stakeholders. The Composite Scheme is proposed to the advantage of all concerned, including the said stakeholders.

**10. NO INVESTIGATION PROCEEDINGS**

There are no proceedings pending under Sections 210 to 227 of the Act against the Applicant Companies.

**11. AMOUNTS DUE TO SECURED CREDITORS, UNSECURED LOAN CREDITORS AND UNSECURED TRADE CREDITORS**

**11.1. SECURED CREDITORS:**

The amount due to secured creditors by the Applicant Companies as on 31<sup>st</sup> March 2025 is as follows:

<b>Sr No.</b>	<b>Particulars</b>	<b>Amount (in INR)</b>
1.	Sequent Scientific Limited (Amalgamated Company)	21,17,10,374
2.	Symed Labs Limited (Transferor Company 1)	20,73,71,057
3.	Vandana Life Sciences Private Limited (Transferor Company 2)	26,35,00,000
4.	Appcure Labs Private Limited (Transferor Company 3)	NIL
5.	Vindhya Pharma (India) Private Limited (Transferor Company 4)	NIL
6.	S.V. Labs Private Limited (Transferor Company 5)	38,74,61,795
7.	Vindhya Organics Private Limited (Transferor Company 6)	11,21,65,662.20
8.	Viyash Life Sciences Private Limited (Transferee Company1/Amalgamating Company 1)	52,30,25,019



9.	Geninn Life Sciences Private Limited (Transferee Company 2/Transferor Company 7)	NIL
10.	Sequent Research Limited (Amalgamating Company 2)	NIL

#### 11.2. UNSECURED LOAN CREDITORS

The amount due to Unsecured Loan Creditors by the Applicant Companies as on 31<sup>st</sup> March 2025 is as follows:

Sr. No.	Particulars	Amount (in INR)
1.	Sequent Scientific Limited (Amalgamated Company)	24,11,55,344
2.	Symed Labs Limited (Transferor Company 1)	NIL
3.	Vandana Life Sciences Private Limited (Transferor Company 2)	NIL
4.	Appcure Labs Private Limited (Transferor Company 3)	NIL
5.	Vindhya Pharma (India) Private Limited (Transferor Company 4)	NIL
6.	S.V. Labs Private Limited (Transferor Company 5)	6,25,916
7.	Vindhya Organics Private Limited (Transferor Company 6)	NIL
8.	Viyash Life Sciences Private Limited (Transferee Company 1/Amalgamating Company 1)	NIL
9.	Geninn Life Sciences Private Limited (Transferee Company 2/Transferor Company 7)	57,00,00,000
10.	Sequent Research Limited (Amalgamating Company 2)	NIL

#### 11.3. UNSECURED TRADE CREDITORS

The amount due to Unsecured Trade Creditors by the Applicant Companies as on 31<sup>st</sup> March 2025 is as follows:

Sr. No.	Particulars	Amount (in INR)
1.	Sequent Scientific Limited (Amalgamated Company)	21,92,13,907
2.	Symed Labs Limited (Transferor Company 1)	1,02,69,32,052
3.	Vandana Life Sciences Private Limited (Transferor Company 2)	74,51,572
4.	Appcure Labs Private Limited (Transferor Company 3)	3,23,64,062.20
5.	Vindhya Pharma (India) Private Limited (Transferor Company 4)	4,20,15,742
6.	S.V. Labs Private Limited (Transferor Company 5)	1,33,13,91,151
7.	Vindhya Organics Private Limited (Transferor Company 6)	1,22,93,12,878
8.	Viyash Life Sciences Private Limited (Transferee Company 1/Amalgamating Company 1)	51,90,19,661.07

9.	Geninn Life Sciences Private Limited (Transferee Company 2/Transferor Company 7)	16,575
10.	Sequent Research Limited (Amalgamating Company 2)	54,62,991

11.4. The Composite Scheme embodies the amalgamation amongst the Amalgamated Company, Transferor Company 1, Transferor Company 2, Transferor Company 3, Transferor Company 4, Transferor Company 5, Transferor Company 6, Transferee Company 1/Amalgamating Company 1, Transferee Company 2/Transferor Company 7, Amalgamating Company 2 and their respective shareholders and /or creditors. No change in value or terms or any compromise or arrangement is proposed under the Composite Scheme with any of the respective creditors of the Applicant Companies.

## 12. CAPITAL /DEBT RESTRUCTURING

There is no capital/debt restructuring envisaged in the Composite Scheme.

## 13. CANCELLATION OF PARTLY PAID-UP EQUITY SHARES OF THE TRANSFEE COMPANY 1.

Upon Part II of the Composite Scheme becoming effective, all equity shares of the Transferee Company 1 which are partly paid-up immediately prior to the Effective Date 1, shall stand cancelled without any further act or deed as an integral part of the Composite Scheme. In lieu of such cancellation, the Transferee Company 1 shall pay the amount paid-up on such partly paid-up equity shares to the relevant shareholders holding such partly paid-up equity shares immediately prior to the Effective Date 1, provided that the Transferee Company 1 shall be entitled to set-off for such amounts any loans or other payments due from such shareholders to Transferee Company 1.

Upon Part II of the Composite Scheme becoming effective and with effect from the Appointed Date, the difference, if any, between the subscribed, issued and paid-up value of equity shares of the Transferee Company 1 which are partly paid-up, as held by the relevant shareholders of Amalgamating Company 1 that is cancelled and the consideration paid to such shareholders pursuant to Clause 4.3 of the Composite Scheme shall be recorded in reserves existing in the Transferee Company 1.

## 14. SUMMARY OF THE VALUATION REPORT AND FAIRNESS OPINION

14.1. Sequent Scientific Limited (“SSL”) engaged M/s. KPMG Valuation Services LLP (“KPMG”), a Registered Valuer Entity having IBBI Registration No. IBBI/RV-E//06/2020/115 and Viyash Life Sciences Private Limited (“VLSPL”) and Geninn Life Sciences Private Limited (“GLSPL”) engaged M/s. PwC Business Consulting Services LLP (“PwC BCS”), a Registered Valuer Entity having IBBI Registration No. IBBI/RV-E/02/2022/158, (collectively referred as “Joint Valuers”) for jointly undertaking and advising the fair valuation for the Composite Scheme.

14.2. A Fair Share Exchange Ratio dated 26<sup>th</sup> September 2024 (“Valuation Report”), was issued by the Joint Valuers, inter-alia, recommending the fair share exchange ratio for the proposed amalgamation, as stipulated in the Composite scheme.

14.3. The summary as submitted by the Joint Valuers of the Valuation Report is as under:

The Fair Share Exchange Ratio has been arrived at on the basis of a relative valuation of

the equity shares of the SSL, VLSPL and GLSPL (hereinafter jointly referred as “**Companies**” and individually referred to as “**Company**”) based on the methodologies explained in the Valuation Report and various qualitative factors relevant to each Company. As stated in the Valuation Report, the Joint Valuers have adopted various methods by assigning appropriate weightages to arrive at the Fair Share Exchange Ratio as follows,

Share Exchange Ratio 1:

“47 (Forty-Seven) equity shares of Viyash Life Sciences Private Limited of INR 10/- each fully paid for every 1 (One) equity share of Geninn Life Sciences Private Limited of INR 10/- each fully paid up.”

Share Exchange Ratio 2:

“56 (Fifty Six) equity shares of Sequent Scientific Limited of INR 2/- each fully paid up for every 100 (One Hundred) equity shares of Viyash Life Sciences Private Limited of INR 10/- each fully paid up.”

Warrant Exchange Ratio:

“56 (Fifty Six) warrants of Sequent Scientific Limited for every 100 (One Hundred) warrants of Viyash Life Sciences Private Limited.”

- 14.4. The Valuation Report provided by KPMG and PwC BCS was approved by the Board of Directors of the Applicant Companies at their respective meetings held on 26<sup>th</sup> September 2024.

A copy of the Joint Valuation Report is enclosed herewith as **Annexure 6**.

## 15. FAIRNESS OPINION

- 15.1. Sequent Scientific Limited (“SSL”) appointed ICICI Securities Limited (“I-Sec”) to provide their independent opinions to the Board of Directors of the SSL on the fairness of Share Exchange Ratio arrived at by the Joint Valuers, from a financial point of view.
- 15.2. I-Sec submitted their fairness opinions vide their reports dated 26<sup>th</sup> September 2024, certifying that, *“In the circumstances, having regard to all relevant factors and on the basis of information and explanations given to us, we are of the opinion on the date hereof, that the Share Exchange Ratio, as recommended by the Registered Valuers is fair.”*
- 15.3. The Fairness Opinion provided by I-Sec was approved by the Board of Directors of SSL at its meeting held on 26<sup>th</sup> September 2024.

A copy of the Fairness Opinion issued by I-Sec is enclosed herewith as **Annexure 7**.

## 16. SHAREHOLDING PATTERN

- 16.1. The shareholding pattern of the Amalgamated Company is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

Category	No. of Equity Shares of Face Value of INR 2/- each	% of holding
Promoter	13,16,80,103	52.61
Public	11,82,12,642	47.23

Non Promoter / Non Public	4,12,250	0.16
<b>Total</b>	<b>25,03,04,995</b>	<b>100.00</b>

- 16.2. The shareholding pattern of the Transferor Company 1 is as follows (based on shareholding data as 30<sup>th</sup> June 2025):

<b>Category</b>	<b>No. of Equity Shares of Face Value of INR 10/- each</b>	<b>% of holding</b>
Promoter	9,30,100	100.00
Public	-	-
<b>Total</b>	<b>9,30,100</b>	<b>100.00</b>

- 16.3. The shareholding pattern of the Transferor Company 2 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

<b>Category</b>	<b>No. of Equity Shares of Face Value of INR 10/- each</b>	<b>% of holding</b>
Promoter	18,55,000	100.00
Public	-	-
<b>Total</b>	<b>18,55,000</b>	<b>100.00</b>

- 16.4. The shareholding pattern of the Transferor Company 3 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

<b>Category</b>	<b>No. of Equity Shares of Face Value of INR 10/- each</b>	<b>% of holding</b>
Promoter	5,18,000	100.00
Public	-	-
<b>Total</b>	<b>5,18,000</b>	<b>100.00</b>

- 16.5. The shareholding pattern of the Transferor Company 4 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

<b>Category</b>	<b>No. of Equity Shares of Face Value of INR 10/- each</b>	<b>% of holding</b>
Promoter	18,69,982	100.00
Public	-	-
<b>Total</b>	<b>18,69,982</b>	<b>100.00</b>

- 16.6. The shareholding pattern of the Transferor Company 5 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

<b>Category</b>	<b>No. of Equity Shares of Face Value of INR 10/- each</b>	<b>% of holding</b>
Promoter	60,38,590	100.00
Public	-	-
<b>Total</b>	<b>60,38,590</b>	<b>100.00</b>

<b>Category</b>	<b>No. of Preference Shares of Face</b>	<b>% of holding</b>
-----------------	---	---------------------

	Value of INR 10/- each	
Promoter	-	-
Public	2,45,00,000	100.00
<b>Total</b>	<b>2,45,00,000</b>	<b>100.00</b>

- 16.7. The shareholding pattern of the Transferor Company 6 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

Category	No. of Equity Shares of Face Value of INR 10/- each	% of holding
Promoter	40,57,548	100.00
Public	-	-
<b>Total</b>	<b>40,57,548</b>	<b>100.00</b>

- 16.8. The shareholding pattern of the Transferee Company 1/Amalgamating Company 1 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

Category	No. of Equity Shares of Face Value of INR 10/- each	% of holding
Promoter & Promoter group	30,05,34,833	89.88
Public	3,38,54,514	10.12
<b>Total</b>	<b>33,43,89,347</b>	<b>100.00</b>

- 16.9. The shareholding pattern of the Transferee Company 2/Transferor Company 7 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

Category	No. of Equity Shares of Face Value of INR 10/- each	% of holding
Promoter	74,097	74.10
Public	25,903	25.90
<b>Total</b>	<b>1,00,000</b>	<b>100.00</b>

- 16.10. The shareholding pattern of the Amalgamating Company 2 is as follows (based on shareholding data as on 30<sup>th</sup> June 2025):

Category	No. of Equity Shares of Face Value of INR 10/- each	% of holding
Promoter	44,10,000	100
Public	-	-
<b>Total</b>	<b>44,10,000</b>	<b>100.00</b>

## 17. PRE /POST SCHEME CAPITAL STRUCTURE

- 17.1. The pre-scheme capital structure of the Amalgamated Company, each of the Transferor Companies and each of the Amalgamating Companies is given in Paragraph 16 above. Pursuant to the Composite Scheme, the post Scheme share capital structure of the Amalgamated Company will be as follows.

- 17.2. The indicative post Scheme share capital structure of the Amalgamated Company will be as follows:

Particulars	Amount (in INR)
<b>Authorized Share Capital</b>	
4,43,07,35,000 Equity shares of Rs.2 each	8,86,14,70,000
<b>Total</b>	<b>8,86,14,70,000</b>
<b>Issued, Subscribed and Paid-up Capital</b>	
42,89,38,532 Equity Shares of Rs.2 each	85,78,77,064
<b>Total</b>	<b>85,78,77,064</b>

**18. AUDITOR'S CERTIFICATE OF CONFORMITY OF ACCOUNTING TREATMENT IN THE SCHEME WITH ACCOUNTING STANDARDS**

In terms of proviso to Sub-section (7) of Section 232 of the Companies Act, 2013, a Certificate from the respective Statutory Auditors of all the Applicant Companies has been obtained to the effect that accounting treatment proposed in the Scheme is in conformity with the Accounting Standards as prescribed under Section 133 of the Companies Act, 2013. The said Certificates have been enclosed herewith as **Annexure 8A to 8J** respectively.

**19. APPROVALS AND INTIMATIONS IN RELATION TO THE SCHEME**

- 19.1. The equity shares of the Company are listed on BSE and NSE. The Company has received observation letters dated 26<sup>th</sup> May, 2025 from BSE and NSE respectively, in terms of Regulation 37 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated 20<sup>th</sup> June, 2023 ("**SEBI Master Circular**"), copies of which are enclosed herewith as **Annexure 9 and 10** respectively.
- 19.2. Further, the Amalgamated Company has not received any complaint relating to the Composite Scheme and "NIL" complaints report were filed by the Amalgamated Company with BSE and NSE in terms of the SEBI Master Circular, copies of which are enclosed herewith as **Annexure 11 and 12** respectively.
- 19.3. As per comments contained in the said observation letters, details of ongoing adjudication & recovery proceedings, prosecution initiated and all other enforcement action taken against the Company, its promoters and directors, as submitted to the Tribunal, are enclosed herewith as **Annexure 13**.
- 19.4. Information pertaining to the all the unlisted entities involved in the Composite Scheme in the format prescribed for abridged prospectus as specified in **Part E of Schedule VI** of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 read with SEBI Circular no. SEBI/HO/CFD/SSEP/CIR/P/2022/14 dated 4<sup>th</sup> February, 2022 is attached hereto. Fortress Capital Management Services Pvt. Ltd., independent SEBI registered merchant bankers, have issued a certificate certifying the accuracy and adequacy of the information in the said abridged prospectus. The said certificate and abridged prospectus of each of the Transferor Companies and each of the



Amalgamating Companies are enclosed herewith as **Annexure 14A to 14I** respectively.

- 19.5. A copy of the Scheme has been filed by the Applicant Companies with the Registrar of Companies, Hyderabad.
- 19.6. The approval of the Competition Commission of India for the Composite Scheme has been obtained vide their order dated 21<sup>st</sup> January, 2025, a copy of which are enclosed herewith as **Annexure 15**.
- 19.7. All approvals as stated in **Clause 74** (Conditions Precedent) of the Scheme, in order to give effect to the Scheme will be obtained.
- 19.8. The Composite Scheme, if approved at this Meeting, shall be subject to subsequent sanction of the Hon'ble Tribunal and such other approval(s), permission(s) and sanction(s) of regulatory or other authorities as may be necessary.

## **20. OTHER ADDITIONAL INFORMATION AS MANDATED BY THE STOCK EXCHANGES AND SEBI**

- 20.1. The following Additional Disclosures are being annexed as required under the Observation letters of **BSE dated 26<sup>th</sup> May 2025** and **NSE dated 26<sup>th</sup> May, 2025** are enclosed herewith as **Annexure 16**:
  - a) Important disclosure in the interest of transparency and informed decision making by public shareholders.
  - b) Need for amalgamation, Rationale of the scheme and swap ratio, Synergies of business of the entities involved in the scheme, Impact of the scheme on the shareholders and cost benefit analysis of the scheme
  - c) Capital build-up of all the unlisted entities involved in the scheme along with the CA certificate certifying the same.
  - d) Details of Revenue, PAT, and EBIDTA of all the companies involved in the Scheme for last 3 years
  - e) Value of Assets and liabilities of Transferor Companies that are being transferred to Transferee Company/ Amalgamated Company and post-merger balance sheet of Amalgamated Company (to be provided for each phase separately).
  - f) Details of shares and warrants being allotted as consideration to GLSPL and VLSPL in below format (separately for both companies).
  - g) Details of the warrants of VLSPL including the date of issuance, its tenure, terms of issuance, terms of its conversion into the warrants issued by SSL and effect on maturity post conversion.
  - h) Clarification letter/certificate issued by the Valuer dated 19<sup>th</sup> May 2025.
  - i) No Objection Certificate (NOC) from the lending scheduled commercial banks/financial institutions/ debenture trustees as per para A(2)(k) of Part -I of SEBI Master Circular.



- j) Details of agreement between VLSPL and GLSPL.
- k) CCI Approval dated 21<sup>st</sup> January 2025
- l) SSL Undertaking dated 07<sup>th</sup> May 2025, on classification of Promoters of VLSPL post the effectiveness of the Scheme.
- m) SSL Undertaking dated 14<sup>th</sup> May 2025 regarding the comments of Registrar of Companies on reduction of partly paid-up shares in the Scheme.
- n) Disclose all pending actions against the entities involved in the Scheme its promoters/directors/KMPs and possible impact of the same on the Transferee Company, to the shareholders.

## **21. INSPECTION OF DOCUMENTS**

In addition to the documents appended hereto, the copies of following documents will be available for inspection by the Equity Shareholders of the Company at its registered office at 3<sup>rd</sup> Floor, Srivallis Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, 500033 between 10:00 a.m. to 12:00 noon IST on all working days from the date hereof up to the date of the Meeting:

- a) Copy of the Tribunal Order;
- b) Copy of Company Application No. C.A.(CAA)/30/HYD/2025 filed jointly by Applicant Companies;
- c) Memorandum and Articles of Association of the Applicant Companies;
- d) Audited financial statements of the Applicant Companies for the year ending 31<sup>st</sup> March 2025;
- e) Composite Scheme;
- f) Agreements material to the Composite Scheme;
- g) Certificates issued by respective statutory auditors of the Applicant Companies confirming that the accounting treatment prescribed under the Scheme is in compliance with Section 133 of the Act and applicable accounting standards; and
- h) All other documents displayed on the Company's website <https://sequent.in/in> in terms of the SEBI Master Circular on the Scheme.

Based on the above, and considering the rationale and benefits, in the opinion of the Board of Directors of the Company, the Composite Scheme will be of advantage to, beneficial and in the best interests of the companies and their respective shareholders, creditors, employees and other stakeholders, and the terms thereof are fair and reasonable. The Board of Directors of the Amalgamated Company recommends the Composite Scheme for the approval of its shareholders.

**Registered Office:**

**SeQuent Scientific Limited CIN:**

**L99999TS1985PLC196357**

3<sup>rd</sup> Floor, Srivallis Corporate, Plot No. 290,  
SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,  
Hyderabad, Shaikpet, Telangana, 500033.

Website: <https://sequent.in/>; E-mail:

[investorrelations@sequent.in](mailto:investorrelations@sequent.in) Tel: +91 22 4111 4777